WO2011070172A1 - Anti-inflammatory agents directed against citrullinated epitopes - Google Patents

Anti-inflammatory agents directed against citrullinated epitopes Download PDF

Info

Publication number
WO2011070172A1
WO2011070172A1 PCT/EP2010/069431 EP2010069431W WO2011070172A1 WO 2011070172 A1 WO2011070172 A1 WO 2011070172A1 EP 2010069431 W EP2010069431 W EP 2010069431W WO 2011070172 A1 WO2011070172 A1 WO 2011070172A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
antibodies
antibody
human
group
Prior art date
Application number
PCT/EP2010/069431
Other languages
French (fr)
Inventor
Jozef Maria Hendrik Raats
Renato Gerardus Silvano Chirivi
Original Assignee
Modiquest B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2012542572A priority Critical patent/JP5980683B2/en
Priority to EP10788080.9A priority patent/EP2509999B1/en
Priority to KR1020127017692A priority patent/KR101786136B1/en
Priority to US15/449,623 priority patent/USRE46990E1/en
Priority to ES10788080.9T priority patent/ES2587083T3/en
Priority to CA2783691A priority patent/CA2783691C/en
Application filed by Modiquest B.V. filed Critical Modiquest B.V.
Priority to AU2010329842A priority patent/AU2010329842B2/en
Priority to US13/514,923 priority patent/US9109019B2/en
Publication of WO2011070172A1 publication Critical patent/WO2011070172A1/en
Priority to US14/742,990 priority patent/US10233236B2/en
Priority to US16/227,047 priority patent/US20190119368A1/en
Priority to US16/984,515 priority patent/US20210087260A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Definitions

  • This invention is in the field of treating or preventing inflammation in humans and animals and relates to pharmaceutical compositions and methods for treating or preventing various inflammatory conditions.
  • the invention relates to compositions and methods for preventing or treating inflammatory conditions such as citrulline related diseases, preferably inflammatory diseases, more preferably
  • the invention provides specific binding molecules such as antibodies directed against citrulline-containing epitopes for use in the therapy and prevention of inflammatory conditions such as inflammatory arthritis, preferably rheumatoid arthritis.
  • Inflammatory conditions whether of a chronic or acute nature, represent a substantial problem in the healthcare industry.
  • chronic inflammation is considered to be inflammation of a prolonged duration (weeks or months) in which active inflammation, tissue destruction and attempts at healing are proceeding simultaneously (Robbins Pathological Basis of Disease by R. S. Cotran, V. Kumar, and S. L. Robbins, W. B. Saunders Co., p. 75, 1989).
  • chronic inflammation can follow an acute inflammatory episode, it can also begin as an insidious process that progresses with time, for example, as a result of a persistent infection (e.g., tuberculosis, syphilis, fungal infection) that causes a delayed hypersensitivity reaction, prolonged exposure to endogenous (e.g., elevated plasma lipids) or exogenous (e.g., silica, asbestos, cigarette tar, surgical sutures) toxins, or autoimmune reactions against the body's own tissues (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, psoriasis).
  • a persistent infection e.g., tuberculosis, syphilis, fungal infection
  • endogenous e.g., elevated plasma lipids
  • exogenous e.g., silica, asbestos, cigarette tar, surgical sutures
  • autoimmune reactions against the body's own tissues
  • rheumatoid arthritis is a multisystem chronic, relapsing, inflammatory disease affecting 1 to 2% of the world's population.
  • RA is basically a severe form of chronic synovitis that sometimes leads to destruction and ankylosis of affected joints (Robbins Pathological Basis of Disease, by R. S. Cotran, V. Kumar, and S. L. Robbins, W.B. Saunders Co., 1989).
  • the disease is characterized by a marked thickening of the synovial membrane which forms villous projections that extend into the joint space, multilayering of the synoviocyte lining (synoviocyte proliferation), infiltration of the synovial membrane with white blood cells (macrophages, lymphocytes, plasma cells, and lymphoid follicles; called an "inflammatory synovitis"), and deposition of fibrin with cellular necrosis within the synovium.
  • the tissue formed as a result of this process is called pannus and eventually the pannus grows to fill the joint space.
  • the pannus develops an extensive network of new blood vessels through the process of angiogenesis, which is essential to the evolution of the synovitis.
  • pannus tissue Release of digestive enzymes (matrix metalloproteinases (e.g., collagenase, stromelysin)), and other mediators of the inflammatory process (e.g., hydrogen peroxide, superoxides, lysosomal enzymes, and products of arachadonic acid metabolism), from the cells of the pannus tissue leads to the progressive destruction of the cartilage tissue.
  • the pannus invades the articular cartilage leading to erosions and fragmentation of the cartilage tissue. Eventually there is erosion of the subchondral bone with fibrous ankylosis, and ultimately bony ankylosis, of the involved joint.
  • RA is an autoimmune disease and that many different arthrogenic stimuli activate the immune response in an immunogenetically susceptible host.
  • exogenous infectious agents Epstein-Barr virus, rubella virus, cytomegalovirus, herpes virus, human T-cell lymphotropic virus, Mycoplasma, and others
  • endogenous proteins such as collagen, proteoglycans, altered immunoglobulins and post-translationally modified proteins like citrullinated proteins have been implicated as a causative agent that triggers an inappropriate host immune response.
  • autoimmunity plays a role in the progression of the disease.
  • the relevant antigen is ingested by antigen-presenting cells (macrophages or dendritic cells in the synovial membrane), processed, and presented to T lymphocytes.
  • the T cells initiate a cellular immune response and stimulate the proliferation and differentiation of B lymphocytes into plasma cells. The end result is the production of an excessive amount of antigen.
  • anti-CCP antibodies have been demonstrated to be highly specific for RA. Recent evidence shows that each individual that is seropositive for these antibodies either already has RA or will develop this disease in the future. The presence of anti-CCP antibodies (especially when high titers are present) is predictive of erosive disease outcome (Nijenhuis et al., Clin. Chim. Acta, vol 350, 17-34, 2004). Furthermore, it has been demonstrated that anti-CCP antibodies are produced locally at the site of inflammation.
  • the invention provides a binding molecule specifically reactive with a citrullinated epitope on p15 and/or p17 for use in the treatment or prevention of inflammatory diseases.
  • P15 and p17 are identified herein as human PAD4 and/or PAD2 deiminated human histone 2A and/or histone 4, and/or on human PAD2 deiminated human histone H3.
  • the invention also provides a method for treating or preventing an inflammatory disease, comprising the step of administering to a patient in need thereof a therapeutically effective amount of an anti-inflammatory composition comprising a binding molecule specifically reactive with a citrulline epitope on p15 and/or p17.
  • compositions and methods of the present invention include pharmaceutically acceptable formulations of specific binding molecules reactive with citrulline residues.
  • the binding molecules are specifically reactive with citrullinated epitopes on two polypeptides as identified herein, termed p 15 and p17.
  • the invention also relates to polypeptides and nucleic acids as identified herein.
  • the invention provides a binding molecule specifically reactive with a citrullinated epitope on p15 and/or p17 for use in the treatment or prevention of inflammatory diseases.
  • binding molecule is used herein to indicate a molecule, preferably a small molecule, capable of specific binding. Specific binding in this respect is intended to mean that the molecule is capable of binding to a selected target molecule whereas it will not bind to another non-related target molecule under the same conditions. For instance, a binding molecule is said to specifically bind to serum albumin when it binds to serum albumin and less or not at all to another or preferably any other protein found in serum.
  • Preferred specific binding molecules are antibodies.
  • peptide should be interpreted as a structure that is capable of presenting the citrulline residue in the correct context for immunoreactivity with the specific binding molecules as described herein, preferably in the same context as it appears in the human or animal body, preferably in the context of a native polypeptide. It is also preferred that the citrullin residue is presented in the context of a native polypeptide that does not activate or trigger other components of the immune system such as cell activation or complement binding.
  • the "specific binding molecule” may be a molecule, preferably a small molecule composed of DNA, RNA, peptide, protein domain, whole proteins, or combinations thereof or parts thereof, that are capable of specifically binding to a target compound.
  • Preferred examples of specific binding molecules are peptides or antibodies.
  • Native antibodies also known as immunoglobulins
  • gamma globulin proteins that may be found in blood or other bodily fluids of vertebrates, and are used by the immune system to identify and neutralize foreign objects, such as bacteria and viruses.
  • Native antibodies are typically made of basic structural units - each with two large heavy chains and two small light chains - to form, for example, monomers with one unit, dimers with two units or pentamers with five units.
  • Antibodies are produced by a white blood cell called a B cell. There are several different types of heavy chains, resulting in different kinds of antibodies. Antibodies may be grouped into different isotypes based on which heavy chain they possess. Five different antibody isotypes are known in mammals which perform different roles, and help direct the appropriate immune response for each different type of foreign object they encounter. Some animal species such as Camelids (e.g. llamas) and sharks may have aberrant antibody structures.
  • the unique part of the antigen recognized by an antibody is called an epitope.
  • These epitopes bind with their antibody in a highly specific interaction that allows antibodies to identify and bind only their unique antigen in the midst of the millions of different molecules that make up an organism.
  • Recognition of an antigen by an antibody tags it for attack by other parts of the immune system.
  • Antibodies can also neutralize targets directly, for example, by binding to a part of a pathogen that it needs to cause an infection.
  • the large and diverse population of antibodies is generated by random combinations of a set of gene segments that encode different antigen binding sites (or paratopes), followed by random mutations in this area of the antibody gene, which create further diversity.
  • Antibody genes also re-organize in a process called class switching that changes the base of the heavy chain to another, creating a different isotype of the antibody that retains the antigen specific variable region. This allows a single antibody to be used in several different isotypes by several different parts of the immune system.
  • antibodies refers to a structure, preferably a protein or polypeptide structure, capable of specific binding to a target molecule often referred to as "antigen”.
  • An antibody may be selected from the group consisting of single chain antibodies, single Chain Variable Fragments (scFvs), Fragment antigen binding regions (Fabs), recombinant antibodies, monoclonal antibodies, fusion proteins comprising the antigen-binding domain of a native antibody or an aptamer, single domains antibodies (sdabs), also known as VHH antibodies, nanobodies (Camelids derived single domain antibodies), shark IgNAR derived single domain antibody fragments called VNAR, Anticalins, aptamers (DNA or RNA) and active components or fragments thereof,
  • an antibody is a fusion protein comprising the antigen-binding domain of a native antibody or an aptamer, such as an aptamer in the form of DNA or RNA.
  • Human antibodies or fragments thereof are a preferred embodiment of the invention.
  • lgG1 e.g., IgGIA
  • antibodies having an lgG1 heavy chain and a lambda light chain may advantageously be used.
  • other human antibody isotypes are also encompassed by the invention, including lgG2, lgG3, lgG4, IgM, lgA1 , lgA2, IgAsec, IgD and IgE in combination with a kappa or lambda light chain.
  • all animal-derived antibodies of various isotypes can be used in the invention.
  • the antibodies can be full-size antibodies or antigen-binding fragments of antibodies, including Fab, F(ab')2, single chain Fv fragments, or single domain VHH, VH or VL single domains.
  • specific binding molecules reactive with a citrullinated epitope are to be interpreted as specific binding molecules that specifically react with a citrulline residue in the context of a larger structure such as a peptide or a peptide nucleic acid or an aptamer or a peptide mimicking structure.
  • Citrulline is an amino acid that is not incorporated into proteins during normal translation, however, it may be generated by post-translational modification of an arginine residue by peptidylarginine deiminase (PAD).
  • PAD peptidylarginine deiminase
  • Citrullination is the posttranslational conversion of arginine residues to citrulline residues, which is catalyzed by peptidylarginine deiminase (PAD).
  • PAD peptidylarginine deiminase
  • Peptidylarginine deiminase (PAD; EC 3.5.3.15) enzymes catalyse the conversion of arginine residues to citrulline residues in proteins. No tRNA exists for citrulline, the presence of citrulline residues in proteins is exclusively the result of post-translational modification. In mammals (humans, mice and rats) five PAD isotypes (PAD1 - PAD6; 'PAD4' and 'PAD5' are used for the same isotype), each encoded by a distinct gene, have been identified (Vossenaar et al, Bioessays 25, 1 106-1 1 18, 2003).
  • Free L-arginine can be converted to free L-citrulline by nitric oxide synthase (EC 1 .14.13.39) in eukaryotes or by arginine deiminase (EC 3.5.3.6) in bacteria. These enzymes are not Ca2+ dependent.
  • PAD1 (synonyms: PAD I, PAD type I) is involved in the citrullination of keratin filaments during the final stages of keratinocyte differentiation, which is important for the reorganization of the cornified envelope.
  • PAD3 sekunder-derived protein
  • THH trichohyalin
  • PAD6 The most recently identified PAD isotype, PAD6 (synonym: ePAD), was found in cytoplasmic sheets of mouse oocytes, which play an important role in early embryogenesis. The expression of its human orthologue was found to be restricted to ovary, testis and peripheral blood leukocytes (Chavanas et al., Gene vol 330; 19-27, 2004). Originally, this PAD isotype was designated ePAD, but based upon the systematic numbering of other PADs, this isotype was renamed PAD6 (Vossenaar et al., Bioessays vol 25 1 106-1 1 18, 2003).
  • PAD2 The most widely expressed isotype, PAD2 (synonyms PAD II, PAD type II, PAD-H19), is present in many different tissues, like skeletal muscle, brain, spleen, secretory glands and macrophages. Despite this broad expression pattern, only myelin basic protein (MBP) and vimentin have been identified as natural substrates. In multiple sclerosis (MS) patients develop an autoimmune response against MBP. MBP is an abundant protein of the myelin sheath, and its citrullination occurs during development of the central nervous system.
  • MBP myelin basic protein
  • MS multiple sclerosis
  • Substrates of PAD4 in the nucleus are histone core proteins (H2A, H3 and H4) and nucleophosmin/B23, a nucleolar protein that functions in ribosome assembly, nucleocytoplasmic transport and centrosome duplication.
  • Specific binding molecules according to the invention are directed against a citrullinated epitope on p15 and/or p17, two polypeptides characterized by their molecular weights of 15 kDa and 17 kDa, respectively.
  • Such specific binding molecules were found to be particularly suited for the treatment or prevention of inflammatory diseases.
  • Inflammatory Conditions or Inflammatory diseases as used herein refers to any of a number of conditions or diseases which are characterized by vascular changes: edema and infiltration of neutrophils (e.g., acute inflammatory reactions);
  • Citrulline related inflammatory diseases are herein defined as those diseases wherein citrullination plays a role in the
  • citrullination plays a role in the pathogenesis of the disease, may be easily determined by a skilled person using routine tests available in the art.
  • these diseases may be characterized by the presence of an abnormal level of citrullinated proteins in affected or disease related tissue. Such may be accomplished by an immunological test such as a western blot or an ELISA wherein the affected tissue is used as an antigen and citrullination of that antigen may be detected with the aid of an anti-citrullin antibody as described herein.
  • Proteomics applications such as mass spec, analysis to compare the level and type of citrullinaton in a diseased versus healthy tissue from affected patients.
  • the disease may also be characterized by the presence of an immune response against citrulline containing peptides or proteins.
  • This may be a humoral or a cellular immune response, such as a response mediated by T-cells or B-cells.
  • Tests for detecting anti-citrulline antibodies have been described in the art and are commercially available.
  • the invention therefore relates to a specific binding molecule for use in treating or preventing citrulline related inflammatory diseases.
  • Such diseases are for instance inflammatory arthritis, including rheumatoid arthritis and osteoarthritis, multiple sclerosis, psoriatic arthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, spondyloarthropathy, Down's syndrome, multiple system atrophy, Parkinson's disease and Lewy body dementia.
  • the invention therefore relates to a specific binding molecule for use in treating or preventing diseases selected from the group consisting of arthritis, rheumatoid arthritis, osteoarthritis, multiple sclerosis, psoriatic arthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, spondyloarthropathy, Down's syndrome, multiple system atrophy, Parkinson's disease and Lewy body dementia.
  • diseases selected from the group consisting of arthritis, rheumatoid arthritis, osteoarthritis, multiple sclerosis, psoriatic arthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, spondyloarthropathy, Down's syndrome, multiple system atrophy, Parkinson's disease and Lewy body dementia.
  • the invention in particular relates to specific binding molecules for the treatment or prevention of autoimmune diseases, more in particular rheumatoid arthritis or osteoarthritis.
  • MS Multiple sclerosis
  • MBP is a highly cationic protein, capable of forming strong interactions with negatively charged phospholipids such as
  • phosphatidylserine In approximately 18% of the MBP molecules of healthy adult humans 6 (out of 19) arginines are citrullinated (Wood et al., J Biol Chem, vol264, 5121 -5127, 1989, Wood et al., Ann Neurol, vol40, 18-24, 1996). The remaining MBP molecules do not contain citrulline. In MS patients the proportion of MBP-cit6 is increased to 45% of total MBP.
  • MBP-cit6 The decreased net positive charge of MBP-cit6 causes partial unfolding of MBP molecules and weakens their interaction with the phospholipids (Boggs et al., J Neurosci Res, vol57, 529-535, 1999, Pritzker et al., Biochemistry, vol39, 5374-5381 , 2000).
  • MBP-cit6 is capable of forming lipid complexes more rapidly than non- citrullinated MBP, the complexes that are formed are not as densely packed as those formed with non-citrullinated MBP (Boggs et al, J Neurosci Res, vol57, 529-535, 1999, Beniac et al, J Struct Biol, vol129, 80-95, 2000). MBP-cit6 is degraded 4 times more rapidly by cathepsin D than non-citrullinated MBP (Cao et al., Biochemistry, vol38, 6157- 6163, 1999).
  • MBPcit18 In a rare case of acute fulminating MS (Marburg type), 80% of the MBP molecules are heavily citrullinated (MBPcit18) (Wood et al., Ann Neurol, vol40, 18-24, 1996). The severely unfolded MBP-cit18 is degraded 45 times more rapidly by cathepsin D than normal MBP (Cao et al., Biochemistry, vol38, 6157-6163, 1999). Clinical trials with paclitaxel, the active component of the anti-cancer drug taxol, are in progress (O'Connor et al., Ann Neurol, vol46, 470, 1999).
  • paclitaxel can inhibit citrullination of MBP by PAD2 in vitro (Pritzker et al., Biochim Biophys Acta, vol1388, 154-160, 1998). Treatment with paclitaxel attenuates clinical symptoms and induces remyelination of damaged sheaths (Moscarello et al., Mult Scler, vol8, 130138, 2002), underlining the possible importance of PAD as a candidate factor in demyelinating disease (Moscarello et al., J Neurochem, vol81 , 335-343, 2002).
  • keratinocytes proliferate very rapidly and travel from the basal layer to the surface in only about four days. The skin can not shed these cells quickly enough so they accumulate in thick, dry patches, or plaques.
  • keratin K1 is citrullinated by PAD1 during terminal differentiation. This process causes the keratin filaments to become more compact, which is essential for the normal cornification process of the epidermis.
  • the keratinocytes in the psoriatic hyperproliferative plaques do not contain citrullinated keratin K1 (Ishida-Yamamoto et al., J Invest Dermatol, vol1 14, 701 -705, 2000).
  • the composition according to the invention is in a form selected from the group consisting of an aqueous solution, a gel, a hydrogel, a film, a paste, a cream, a spray, an ointment, or a wrap.
  • the above methods are used to administer the compositions described herein by a route selected from intra-articular, intraperitoneal, topical, rectal, intravenous, oral, ocular, or to the resection margin of tumors.
  • a pharmaceutically acceptable carrier comprises at least one carrier selected from the group consisting of a co-solvent solution, liposomes, micelles, liquid crystals, nanocrystals, nanoparticles, emulsions,
  • a polysaccharide comprises hyaluronic acid and derivatives thereof, dextran and derivatives thereof, cellulose and derivatives thereof (e.g., methylcellulose, hydroxy-propylcellulose, hydroxy-propylmethylcellulose, carboxymethylcellulose, cellulose acetate phthalate, cellulose acetate succinate, cellulose acetate butyrate,
  • hydroxypropylmethyl-cellulose phthalate chitosan and derivative thereof, [beta]-glucan, arabinoxylans, carrageenans, pectin, glycogen, fucoidan, chondrotin, dermatan, heparan, heparin, pentosan, keratan, alginate, cyclodextrins, and salts and derivatives, including esters and sulfates, thereof.
  • the method according to the invention comprises delivering a composition according to the invention to a target site, most notably a synovial joint.
  • the specific binding molecule competes with monoclonal antibodies RhmAb2.102, RhmAb2.108,
  • histone 3 h2bb [Mus musculus]
  • histone cluster 2 H4 [ attus norvegicus]
  • histone cluster 2 H4 [Rattus norvegicus]
  • histone cluster 2 H4 [Rattus norvegicus]
  • Binding molecules or antibodies competing with the monoclonal antibodies as disclosed herein may be selected by standard procedures.
  • a binding assay such as an ELISA may be developed wherein the antigens as disclosed herein are immobilized on a solid support.
  • the monoclonal antibodies as disclosed herein may be labeled and interference with their binding to the immobilized antigens may be easily determined by routine analysis.
  • assays may easily be developed using any of the antigenic proteins according to SEQ ID NO: 21 , SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 37 and SEQ ID NO: 38 immobilized on a solid support.
  • Monoclonal antibodies selected from the group consisting of RhmAb2.102, RhmAb2.108, RhmAb2.109, RhmAb2.1 10,
  • RhmAb2.1 1 1 RhmAb2.1 12 and RmmAb 22.101 may be labeled and contacted with the immobilized antigen in the presence and the absence of a test antibody. If the test antibody interferes with the binding, i.e. lowers the signal obtained with any of the labeled antibodies, it may be concluded that the test antibodie competes with binding of the labeled antibody. Such a competing antibody would then be suitable for use in the methods of the invention.
  • the invention therefore relates to an antibody for use in the treatment or prevention of rheumatoid arthritiswherein the antibody is specifically reactive with a peptide selected from the group consisting of SEQ ID NO: 21 , SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 37 and SEQ ID NO: 38.
  • the primary mRNA sequences of the variable regions of monoclonal antibody RhmAb2.101 have been published and were deposited in the EMBL database under accession numbers as shown in table 1 .
  • RhmAb2.1 10, RhmAb2.1 1 1 and RhmAb2.1 12 are disclosed herein in SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 39, SEQ ID NO: 20, SEQ ID NO: 41 , SEQ ID NO: 40, SEQ ID NO: 19, SEQ ID NO: 43, and SEQ ID NO: 42
  • the invention therefore also relates to a polypeptide comprising a variable heavy or light chain selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 , SEQ ID NO: 19, SEQ ID NO: 43, SEQ ID NO: 42, SEQ ID NO: 44 and SEQ ID NO: 45.
  • the invention also relates to a nucleic acid encoding a polypeptide selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 , SEQ ID NO: 19, SEQ ID NO: 43, SEQ ID NO: 42, SEQ ID NO: 44 and SEQ ID NO: 45.
  • the invention also relates to a polypeptide comprising a variable heavy and light chain as is present in Rmm22.101 and RmmAb22.102.
  • the invention also relates to a nucleic acid encoding a polypeptide according a variable heavy and light chain as is present in RmmAb22.101 and
  • RmmAb22.102 which is shown in SEQ ID NO: 44 and SEQ ID NO: 45.
  • the specific binding molecule is an antibody selected from the group consisting of monoclonal antibodies RhmAb2.102, RhmAb2.108, RhmAb2.109, RhmAb2.1 10, RhmAb2.1 1 1 and RhmAb2.1 12,
  • the specific binding molecule comprises VH and /or VL domains derived or obtained from an antibody selected from the group consisting of monoclonal antibodies and RhmAb2.102, RhmAb2.108, RhmAb2.109, RhmAb2.1 10, RhmAb2.1 1 1 and RhmAb2.1 12, RmmAb22.101 , and RmmAb22.102.
  • derived in this context means that the primary structure of the VH and/or VL domains may be determined from the protein and nucleic acid sequences disclosed herein and cloned and rearranged in a different context, for instance a human antibody context displaying a mouse VH or VL domain. More in particular, the term “derived” or “obtained”in this respect means that the essential residues responsible for the specific binding properties of the VH and /or VL domains in a particular antibody are identified and that these essential residues or structural homologues thereof are then transferred into the context of another peptide.
  • Specific binding molecules according to the invention may be generated essentially in two ways. First, they may be derived from the antibodies and its sequences as presented herein. Reactivity of the antibodies may even be improved by side-directed mutagenesis, chain shuffling, sexual PCR, or by other means for antibody derivation and optimisation known to the person skilled in the art. Alternatively, specific binding molecules, in particular antibodies may be obtained by panning with any of the specifically reactive epitopes as described herein, in particular deiminated Histon 2A, peptide 1 (SEQ ID NO: 21 ) and other particularly reactive peptides.
  • a person skilled in the art may use the sequences described herein to clone or generate cDNA or genomic sequences for instance such as described in the below examples. Cloning of these sequences in an appropriate eukaryotic expression vector, like pcDNA3 (In Vitrogen), or derivates thereof, and subsequent transfection of mammalian cells (like CHO cells) with combinations of the appropriate light chain and heavy chain containing vectors will result in the expression and secretion of the listed antibodies RhmAb2.102, RhmAb2.108, RhmAb2.109, RhmAb2.1 10, RhmAb2.1 1 1 and RhmAb2.1 12, RmmAb22.101 , and RmmAb22.102. Also, mouse monoclonals
  • RmmAb22.101 and RmmAb22.102 may be directly expressed and secreted by their respective hybridoma cell lines as deposited. (DSMZ numbers ACC 3031 and ACC 3032)
  • the skilled person may also make analogues of the specific binding molecules as described herein by using the specific binding domains of the antibody sequences and express them in a different context such as a polypeptide such as a fusion protein. This is well known in the art.
  • Recombinant Human and Mouse monoclonal anti-citrulline antibodies were obtained as described in Examples 1 , 13, and 14.
  • Monoclonal antibody heavy chains RhmAb2.102, RhmAb2.108, RhmAb2.109, RhmAb2.1 10, RhmAb2.1 1 1 and RhmAb2.1 12 were obtained with a mouse leader sequence (SEQ ID NO: 12), and a human lgG1 Fc region (SEQ ID NO: 14).
  • Monoclonal antibody light chains RhmAb2.102, RhmAb2.108, RhmAb2.109, RhmAb2.1 1 1 and RhmAb2.1 12 were obtained with a mouse leader sequence (SEQ ID NO: 12) and a human Lambda constant region (SEQ ID NO: 16).
  • Monoclonal antibody RhmAb2.1 10 was obtained with a mouse leader sequence (SEQ ID NO: 12) and a human Kappa constant region (SEQ ID NO: 1 1 ).
  • Mouse monoclonal anti-citrullin-peptide antibodies RmmAb13.101 , RmmAb13.102 and RmmAb13.103 were obtained from a commercial source (ModiQuest Research BV Nijmegen, The Netherlands; Cat no, MQ13.101 , MQ13.102and MQ13.103).
  • Anti-citrullin antibodies were tested in an experimental model wherein inflammation is induced by injecting anti-collagen antibodies into a mouse. This model is known as collagen antibody induced arthritis (CAIA) (Nandakumar and Holmdahl, J Immunol Methods, vol304, 126-136, 2005). Anti collagen antibodies were obtained from a commercial source (ModiQuest Research BV Nijmegen, The Netherlands; Cat no, MQ18.101 ).
  • RmmAb13.102 and RmmAb13.103 were confirmed to enhance the severity of the collagen antibody induced arthritis, as has been described also by Kuhn et al. (J. Clin. Invest, vol1 16, 961 -871 , 2006); and Hill et al. (J Exp Med, vol 205, 967-979, 2008). This is shown in figures 1 a and 1 b.
  • RhmAb2.102 dramatically reduced the clinical signs of arthritis in the experimental CAIA model.
  • RhmAb2.102 Results obtained with RhmAb2.102 are shown in Figures 1 c and 1 d. Results obtained with RhmAb2.108, RhmAb2.109, RhmAb2.1 10, RhmAb2.1 1 1 and RhmAb2.1 12 were even better as compared to RhmAb2.102, as shown in Figure 9.
  • the human monoclonal antibody RhmAb2.101 had no effect at all on the clinical signs of arthritis at the dose applied.
  • the commercially available antibody RhmAb2.201 is used as an irrelevant antibody control in this experiment (ModiQuest Research B.V., cat no: MQR2.201 ). This antibody does not recognize citrulinated epitopes.
  • Figure 1 e and 1f show an independent CAIA experiment in which the clinical dose for RhmAb2.102 has been evaluated.
  • the lowest dose that gave maximum inhibition was 0,5 mg Ab/mouse which corresponds to 28 mg/kg at IP injection.
  • RmmAb22.101 , and RmmAb22.102 play an important role in the treatment or prevention of inflammatory diseases. Specific masking of these epitopes may therefore be an effective therapy of inflammatory diseases, in particular rheumatoid arthritis.
  • WO 2004/078098 discloses antibodies specific for citrullinated peptide/MHC class II complexes to inhibit T cell activation. These antibodies do not bind to the separate peptide or MHC class II molecule but only to the complex of the peptide and the MHC class II molecule.
  • the antibodies disclosed herein are different from the antibodies disclosed in WO 2004/078098 since they recognize the individual peptides and proteins as disclosed herein.
  • the antibodies recognize a polypeptide in a western blot that could not be a complex between a peptide and an MHC class II molecule, since the complex between an MHC molecule and a citrullinated peptide would never survive the reducing conditions of an SDS gel used in the immunoblot procedure.
  • the epitopes recognized by the binding molecules as disclosed herein are therefore different from the antibodies disclosed in WO 2004/078098.
  • the antibodies as disclosed herein are not specifically reactive with a complex of a peptide and an MHC class II molecule.
  • RmmAb22.101 may be performed using either Western blots containing deiminated COS-1 lysates or purified deiminated p15 and/or p17 proteins in Western blot or ELISA.
  • Proteins p15 and p17 were further characterized by Matrix-assisted laser desorption/ionisation-time of flight mass spectrometry (MALDI-TOF MS) as detailed in example 6. Since the genome of the African Green Monkey is not completely sequenced we screened all other mammal genome databases for homology with the peptides found with MALDI-TOF MS. Proteins found with a high degree of homology turned out to be histones. This is shown in Table 3 (Example 6).
  • the invention therefore also relates to a binding molecule specifically reactive with a citrullinated epitope on histones for use in the treatment or prevention of inflammatory diseases.
  • citrullinated histones may very well be produced in vitro. These citrullinated histones may then be used as a substrate in an enzymatic binding assay to screen and select for other specific binding molecules such as peptides and antibodies reactive with epitopes on citrullinated p15 and p17, i.e. histones.
  • specific binding molecules are selected that compete with antibodies RhmAb2.102, RhmAb2.108, RhmAb2.109, RhmAb2.1 10, RhmAb2.1 1 1 and RhmAb2.1 12,
  • RmmAb22.101 and RmmAb22.102 for binding to p15 and/or p17.
  • RhmAb2.102 RhmAb2.108, RhmAb2.109, RhmAb2.H 0, RhmAb2.1 1 1 and RhmAb2.1 12, RmmAb22.101 , and RmmAb22.102
  • commercial available histones H1 , H2A, H2B, H3 and H4 were deiminated with human
  • PAD peptidylarginine deiminase
  • huPAD2 or huPAD4 enzymes
  • RhmAb 2.102 and RhmAb 2.101 are highest for Human PAD2 and/or PAD4 deiminated H2A, Human PAD 2 deiminated Histon 3, and Human PAD 4 and/or PAD 2 deiminated Histon 4.
  • a mimic is for instance a molecule with an acceptable level of equivalent activity, which, in this case, would include as being recognized with higher affinity by RhmAb2.102 as compared to RhmAb2.101 .
  • the invention therefore relates to a specific binding molecule as described above, reactive with a citrullinated epitope on human PAD4 or Human PAD 2 deiminated human histone 2A or histone 4, or on human PAD2 deiminated histone H3.
  • biotin labeled peptides as shown in table 4 were synthesized containing potential deimination sites of histone 2A. These peptides were coated on 96-well neutravidin-ELISA plates and incubated with serial dilutions of RhmAb2.101 and
  • RhmAb2.102. The results are shown in Figure 3.
  • Table 6A Reactivity of deiminated histones with RhmAb2.101 , shown in figure 2A
  • the specific binding molecules according to the invention may also be defined by their reactivity towards peptides 1 , 4 and 6; SEQ ID NO: 21 , SEQ ID NO: 24 and SEQ ID NO: 26 respectively.
  • Each of these citrulline containing peptides or derivatives thereof, individually, or a combination of such peptides, or structures containing on or more of such peptide sequences, may be used to generate specific binding molecules such as antibodies according to the invention. Such antibodies may then be selected towards any of the other antigens as disclosed herein for optimal reactivity.
  • Biotin labeled and citrullin containing fibrinogen and vimentin peptides were also tested for reactivity with the therapeutic antibodies. Peptides were coated on 96-well neutravidin-ELISA plates. Subsequently serial dilutions of RhmAb2.101 ,
  • RhmAb2.102 were applied to the coated plates. The results are shown in Table 8 and Figure 4.
  • the invention therefore also relates to a specific binding molecule as described above which is specifically reactive with an epitope on peptides msFib3 or msVim (SEQ ID NO: 37 or SEQ ID NO: 38) and their use.
  • citrullinated epitopes appear de novo in inflammated tissue.
  • human monoclonal antibody 102 RhmAb2.102
  • mice 3 mice per group
  • mice Three days later mice received another i.p. injection containing 25ug LPS. Scoring has been performed as described above.
  • a group of mice has been sacrificed, and paws were analyzed for citrulline presence by Western Blot analysis and Immunohistochemical techniques.
  • IP Immuniprecipitations
  • citrulline residues present on blot have been chemically modified according to Senshu et al. (Senshu et al, Anal Biochem, vol 203, 94-100, 1992).
  • the chemical modification can then be visualized using an antibody that recognizes the chemical modification of citrulline residues (Senshu et al, Anal Biochem, vol 203, 94-100, 1992).
  • Deiminated fibrinogen was used as a positive control in this experiment.
  • An immunoprecipitation without extracts was used as a negative control in these
  • mice subjected to CAIA have detectable citrulline levels in their inflamed joints.
  • anti-citrulline antibodies were injected on day 3 after anti-collagen antibody injection, when inflammation in the paws of mice was still absent or very low. This prevented the occurrence of clinical symptoms and is therefore useful as a treatment of inflation, in particular a prophylactic treatment.
  • RhmAb2.102 could also cure clinical symptoms once they had occurred. This was done by treating animals on day 7 after anti- collagen injection when mean arthritis scores of all 4 paws of all mice reached the arbitrary score of approximately 4. As is shown in figure 6A and 6B, RhmAb2.102 does not abolish the swelling observed, but rather stabilized the present inflammation/swelling. Animals were followed for 35 days after which inflammatory scores among placebo and RhmAb2.102 treated mice were equal ( Figure 6B and example 10). Figure 6A shows the Mean arthritis score of all paws of each group, while Figure 6B shows the mean arthritis score of the right hind paws of the animals that have been used for histological analysis at day 35.
  • FIG. 7A shows that macroscopical inflammation in the right hind paws between experimental groups on day 35 of the experiment were similar. Most surprisingly however, all known parameters for joint erosion were decreased.
  • D Inflammatory cell influx
  • B Cartilage erosion
  • E Cartilage PG depletion
  • F Chondrocyte death
  • C Bone erosion
  • RhmAb2.102 has been injected i.v. in order to deliver the antibody rapidly to sites of inflammation.
  • prophylactic treatment at day 3 and a non treated control group have been included.
  • Experimental procedures have been performed as in Example 10 with the only difference of injections with 1 mg RhmAb2.102 per mouse on day 3, 5 and 6.
  • RhmAb2.102 at day 3 inhibited the inflammatory response.
  • Treating mice with i.v. injections of RhmAb2.102 on day 5, 6 or 7 stabilized the inflammation ( Figure 8) as also seen in Figure 6. It is noteworthy that the signs of inflammation were not reduced whereas all parameters for joint erosion were decreased. This shows that joint erosion and inflammation are two separate entities that may be treated separately.
  • RhmAb2.102 Additional deiminated proteins that preferentially bind to RhmAb2.102 have been identified by mass spectrometry analysis. Furthermore, deiminated proteins that preferentially bind to RhmAb2.102 and not, or with to a lesser extent to RhmAb2.101 have also been identified by additional mass spectrometry analysis.
  • Human PAD4 deiminated Human Embryonic Kidney cell (HEK293) lysates have been immunoprecipitated with RhmAb2.101 or RhmAb2.102 (Example 1 1 ) and subjected to a high throughput nano-LC system coupled to an advanced, high-performance LTQ Fourier Transform Ion Cyclotron Resonance Mass spectrometer (nl_C LTQ FTMS ULTRA) (Example 12).
  • the invention also relates to a binding molecule specifically reactive with any of the proteins or polypeptides as shown in table 7 for use in the prevention or treatment of an inflammatory disease.
  • a binding molecule specifically reactive with an epitope on a molecule selected from the group consisting of p15, p17, more in particular a citrullinated epitope on human PAD4 and/or PAD2deiminated human histone 2A, a citrullinated epitope on human PAD4 deiminated human histone 4, human PAD2 deiminated human histone H4, human PAD2 deiminated human histone H3, or a protein selected from the group consisting of the proteins of table 9 and even more in particular a peptide according to SEQ ID NO: 21 , SEQ ID NO: 24, SEQ ID NO 26, SEQ ID NO: 37 and SEQ ID NO: 38 may be used in the treatment or prevention of inflammatory diseases as specified herein.
  • Whether a given binding molecule is specifically reactive with the above mentioned molecules may easily be determined by analysis of the ability of the binding molecule to compete with an antibody selected from the group consisting of RhmAb2.102, RhmAb2.108, RhmAb2.109, RhmAb2.1 10, RhmAb2.1 1 1 and RhmAb2.1 12, RmmAb22.101 , and RmmAb22.102 for binding to an epitope on p15 or p17 or any of the citrullinated epitopes mentioned above.
  • inflammatory diseases may also be treated or prevented by eliciting an immune response wherein specific binding molecules according to the invention are generated in the patient's own body (in vivo).
  • an immune response may be generated to prevent inflammatory disease from occurring (prophylaxis, prophylactic vaccines) or to ameliorate or decrease the
  • the invention also relates to a method for the prevention or treatment of inflammatory diseases by eliciting an immune response in vivo wherein specific binding molecules are generated reactive with an epitope selected from the group consisting of a citrullinated epitope on p15, p17, a citrullinated epitope on human PAD4 and/or PAD 2 deiminated human histone 2A, human PAD4 and/or PAD 2 deiminated human histone 4, human PAD2 deiminated human histone H3, and a peptide according to SEQ ID NO: 21 , SEQ ID NO: 24, SEQ ID NO 26, SEQ ID NO: 37 and SEQ ID NO: 38
  • Vaccines or therapeutics according to the invention may effectively comprise a citrullinated epitope specifically reactive with a binding molecule according to the invention.
  • the citrullinated epitope may be a citrullinated epitope on human PAD4 and/or PAD 2 deiminated human histone 2A, human PAD4 and/or PAD 2 deiminated human histone 4, human PAD2 deiminated human histone H3, or a peptide selected from the group consisting of SEQ ID NO: 21 , SEQ ID NO: 24, SEQ ID NO 26, SEQ ID NO: 37 and SEQ ID NO: 38.
  • the invention also relates to a method as described above wherein the inflammatory disease is selected from the group consisting of autoimmune diseases, arthritis, rheumatoid arthritis, osteoarthritis, multiple sclerosis, psoriatic arthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, spondyloarthropathy, Down's syndrome, multiple system atrophy, Parkinson's disease and Lewy body dementia.
  • the inflammatory disease is selected from the group consisting of autoimmune diseases, arthritis, rheumatoid arthritis, osteoarthritis, multiple sclerosis, psoriatic arthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, spondyloarthropathy, Down's syndrome, multiple system atrophy, Parkinson's disease and Lewy body dementia.
  • autoimmune diseases such as rheumatoid arthritis.
  • a preferred specific binding molecule is an antibody.
  • peptides and proteins as mentioned herein may also be used as antigens for the detection of specific antibodies in order to diagnose inflammatory diseases, more preferably Rheumatoid Arthritis.
  • FIG. 1 A Collagen antibody induced arthritis (CAIA) model was used to test the effect of monoclonal antibodies on the severity of symptoms of arthritis. Mean arthritis score ( Figures 1 a, 1 c and 1 e) and arthritis incidence (figures 1 b, 1 d and 1f) are indicated.
  • CAIA Collagen antibody induced arthritis
  • mice used in the experiments shown in figure 1 a and 1 b received 1 ,6 mg anti- collagen antibody mix, whereas mice used in figure 1 c-f received 2,4 mg.
  • LPS 25 ⁇ g mouse
  • anti-citrulline or a control antibody RhmAb2.201
  • FIG. 2 An enzyme linked immunosorbend assay (ELISA) was used to test the affinity of a) RhmAb2.101 and b) RhmAb2.102 for human recombinant histones (H1 , H2A, H2B, H3 and H4) deiminated with huPAD2 or huPAD4. Deiminated as well as non-deiminated histones were immobilized on 96-well ELISA plates (O ⁇ g/well). CFC-1 and CFC-0 were coated at the same concentration and served as positive and negative controls respectively for specific anti-citrulline reactivity and as coating controls. Non coated wells were used to test for aspecific binding of the antibodies.
  • ELISA enzyme linked immunosorbend assay
  • FIG. 3 An enzyme linked immunosorbend assay (ELISA) was used to test the affinity of a) RhmAb2.101 and b) RhmAb2.102 for citrulline containing peptides derived from human histones H2A. Biotin and citrulline containing peptides derived from histone 2A were immobilized on neutravidin coated 96-well ELISA plates (0 ⁇ g/well). CFC-1 and CFC-0 were coated at the same concentration and served as positive and negative controls respectively for specific anti-citrulline reactivity and as coating controls. Non coated wells were used to test for aspecific binding of the antibodies.
  • ELISA enzyme linked immunosorbend assay
  • Coated wells were incubated with antibody dilution series ranging from 10ug/well down to 0,000128ug/well for 1 h at RT (z- axis). Detection of bound anti-citrulline antibodies was performed by incubating the wells with rabbit-anti-human-HRP (1 :2000) for 1 hour at RT followed by incubation with TMB substrate. The resulting OD (y-axis) is a measure for antibody binding.
  • Figure 4 An enzyme linked immunosorbend assay (ELISA) was used to test the affinity of a) RhmAb2.101 and b) RhmAb2.102 for citrulline containing peptides derived from fibrinogen and vimentin.
  • ELISA enzyme linked immunosorbend assay
  • Biotin and citrulline containing peptides derived from fibrinogen and vimentin were immobilized on neutravidin coated 96-well ELISA plates (0 ⁇ g/well).
  • CFC-1 and CFC-0 were coated at the same concentration and served as positive and negative controls respectively for specific anti-citrulline reactivity and as coating controls.
  • Non coated wells were used to test for aspecific binding of the antibodies. Coated wells were incubated with antibody dilution series ranging from 10ug/well down to
  • FIG. 5 A Collagen antibody induced arthritis (CAIA) model was used to investigate citrulline appearance in the paws. Groups of 3 mice were treated at day 0 with 2.8mg anti- collagen antibodies through i.p. injection, followed by an additional i.p. injection with LPS (25 ⁇ g mouse) on day 3. Mean arthritis score and arthritis incidence are shown in Figure 5A and 5B respectively.
  • CAIA Collagen antibody induced arthritis
  • FIG. 6 A Collagen antibody induced arthritis (CAIA) model was used to test the therapeutic effect of RhmAb2.102 when given on day 7 after anti-collagen antibody injection. Mean arthritis score of all paws ( Figure 6A) and Mean arthritis score of the right hind paws ( Figure 6B) are indicated. Groups of 5 mice were treated at day 0 through i.p. injection with 2,8mg anti-collagen antibodies. LPS (25 ⁇ g mouse) was administered on day 3 through i.p. injection, and RhmAb2.102 (1 mg/mouse) or placebo were injected via the same route at day 7. Animals have been scored daily until day 35. It was observed that RhmAb2.102 at least stabilized the present inflammation.
  • CAIA Collagen antibody induced arthritis
  • Figure 7 Histological analysis has been performed on Haematoxylin/eosin and safranin O stained tissue slides of right hind paws of all CAIA animals that have been treated on day 7 with RhmAb2.102 or placebo (Figure 7). The following parameters have been scored (arbitrary scale of 0-3) on the stained tissue slides: Cartilage erosion (B), Bone erosion (C), Inflammatory cell influx (D), Cartilage PG depletion (E), and Chondrocyte death (F).
  • Figure 7A shows the macroscopical inflammation in the right hind paws between experimental groups on the last day of the experiment (day 35). Each dot depicts a single animal. The horizontal lines indicate the mean score within an experimental group. It may be concluded that RhmAb2.102 injection protects the mice from permanent joint damage.
  • FIG. 8 A Collagen antibody induced arthritis (CAIA) model was used to test the therapeutic effect of RhmAb2.102 when given on day 3, 5, 6 and 7 days after injection of anti-collagen antibodies.
  • Groups of 5 mice were treated at day 0 through i.p. injection with 2,8mg anti-collagen antibodies.
  • LPS 25 ⁇ g/mouse
  • RhmAb2.102 (1 mg/mouse) was injected i.v. at day 3, 5, 6 or 7. Animals have been scored daily until day 19.
  • the graph depicts Mean arthritis score for each experimental group. It may again be concluded that RhmAb2.102 at least stabilized the inflammation at a level comparable to the level at the start of the therapy.
  • RhmAb2.1 1 1 and RhmAb2.1 12 when given on day 3 after injection of anti-collagen antibodies. Mean arthritis score of all paws are indicated. Groups of 3 mice were treated at day 0 with i.p. injection of 2,8mg anti-collagen antibodies. LPS (25 ⁇ g mouse) was administered at day 3 via i.p. injection, and RhmAb2.102, RhmAb2.108,
  • RhmAb2.109, RhmAb2.1 10, RhmAb2.1 1 1 and RhmAb2.1 12 (1 mg/mouse) or placebo were injected via i.v. injection on the same day. Animals have been scored daily until day 14.
  • RhmAb2.1 12 showed a higher anti-inflammatory effect than RhmAb2.102.
  • FIG. 10 The Collagen antibody induced arthritis (CAIA) model was used to test the anti inflammatory effect of RhmAb2.102, RmmAb22.101 , and RmmAb22.102 antibodies.
  • CAIA Collagen antibody induced arthritis
  • mice Groups of 3 mice were treated at day 0 with i.p. injection of 2,8mg anti-collagen antibodies.
  • LPS 25 g/mouse
  • RhmAb2.102 RhmAb2.102
  • RmmAb22.101 RhmAb2.102
  • RmmAb22.102 (6mg/mouse) and placebo were administered via i.p. injection on day 3. All animals have been scored for inflammation daily until day 10.
  • RhmAb2.102 protected the mice against inflammation in their paws. Only data of RhmAb2.102 and RmmAb22.101 are shown.
  • Figure 1 1 An enzyme linked immunosorbend assay (ELISA) was used to test the affinity of A) RhmAb2.102, B) RhmAb2.108, C) RhmAb2.109, D) RhmAb2.1 10, E) RhmAb2.1 1 1 , F) RhmAb 2.1 12, G) RmmAb22.101 , and H) RmmAb22.102 for human recombinant histones (H1 , H2A, H2B, H3 and H4) deiminated with huPAD2 or huPAD4. Deiminated as well as non-deiminated histones, and BSA were immobilized on 96-well ELISA plates (0,3 g/well).
  • ELISA enzyme linked immunosorbend assay
  • CFC-1 , CFC-0, SEQ ID NO: 21 were coated at the same concentration and served as positive and negative controls respectively for specific anti-citrulline reactivity and as coating controls.
  • Non coated wells were used to test for aspecific binding of the antibodies.
  • Coated wells were incubated with antibody dilution series ranging from 2,5 ug/well down to 0,004ug/well for 1 h at RT (z-axis). Detection of bound anti-citrulline antibodies was performed by incubating the wells with rabbit-anti-human-HRP (1 :2000) for 1 hour at RT followed by incubation with TMB substrate. The resulting OD (y-axis) is a measure for antibody binding.
  • Example 1 Recombinant human and mouse monoclonal antibodies.
  • Monoclonal antibodies against citrullinated antigens of patients with RA were initially selected by means of phage display, as described (Raats et al., J
  • Antibody coding sequences described by Raats et al., (J Reumatology, vol30, 1696-71 1 , 2003) were synthesized according to Stemmer et al (Gene, vol164, 49- 53, 1995), and subsequently cloned into mammalian expression vectors coding for human and mouse antibody isotypes.
  • Human antibodies were of the isotype lgG1 lambda and were named RhmAb2.101 , RhmAb2.102.
  • RhmAb2.101 was synthesized according to the protocol of Stemmer et al., (Gene, vol164, 49-53, 1995) based on the sequence of clone Ra3 (Raats et al., J Reumatology, vol30, 1696-71 1 , 2003) and consists of a VH derived from germline family 3-21 , combined with a VL derived from germline family ⁇ 1 b..
  • RhmAb2.102 was synthesized according to Stemmer et al (Gene, vol164, 49-53, 1995) and comprises an immunoglobulin heavy chain encoded by SEQ ID NO: 8, combined with an immunoglobulin light chain encoded by SEQ ID NO: 9.
  • the immunoglobulin heavy chain encoded by SEQ ID NO: 8 comprises a mouse leader globulin according to SEQ ID NO: 12, followed by the variable antibody heavy chain according to SEQ ID NO: 13, followed by the immunoglobulin constant domain human lgG1 according to SEQ ID NO: 14.
  • the immunoglobulin light chain encoded by SEQ ID NO: 9 comprises a mouse leader globulin according to SEQ ID NO: 12, followed by the variable antibody light chain according to SEQ ID NO: 15 followed by the immunoglobulin human lambda constant domain according to SEQ ID NO: 16.
  • variable domains VH and VL
  • VH and VL variable domains of monoclonal antibody RhmAb2.101
  • Table 1 The primary mRNA sequences of the variable domains (VH and VL) of monoclonal antibody RhmAb2.101 have been published and were deposited in the EMBL database under accession numbers as shown in table 1. Full size human antibody sequences were generated using identical leader and constant human domains as described for antibody RhmAb2.102. Table 1
  • CAIA collagen antibody induced arthritis
  • mice For that purpose, on day 0 male DBA/J1 mice (5-6 mice /group) of the age of 8 weeks have been injected i.p. with a mix of 8 anti-collagen antibodies. (Mice used in figure 1 a and 1 b received 1 ,6mg anti-collagen antibody mix, whereas mice used in figure 1 c-f received 2,4mg). On day 3, mice received another i.p. injection containing 25ug LPS mixed with 1 mg anti-citrulline antibodies (unless stated otherwise). LPS triggers the inflammation. Until day 13 of the experiment animals where scored daily for signs of inflammation in their paws. Scoring has been performed according to the table 2. The maximum arthritis score per animal is 8.
  • RhmAb2.102 Human monoclonal antibody RhmAb2.102, reduced or even abolished the clinical signs of arthritis in the experimental CAIA model, whereas RhmAb2.101 had no effect at all at the dose tested ( Figure 1 c and 1 d).
  • Example 3 Preparation of deiminated cell extract, SDS-page electrophoresis and western blotting.
  • COS-1 cells (8 10 5 ) were transiently transfected with 2 ⁇ g huPAD2 or huPAD4 expression vector using the AMAXA nucleofection device (program D-005) together with the V-kit, and cells were seeded in 20ml medium in a T75.
  • the cells were washed twice with PBS, trypsinized, spun down and resuspended in 15 ⁇ ice cold lysis buffer (20mM Tris pH7.4, 10mM ⁇ - mercaptoethanol, 100mM NaCI, 10% glycerol, protease inhibitors).
  • the cell samples were sonified 4 times for 15 seconds on ice.
  • the lysate was centrifuged at 3.000 rpm for 5 minutes and the supernatant transferred to a clean tube.
  • the cell lysate was deiminated for 30 minutes to 2 hours at 37°C by adding CaCI 2 and DTE at a final concentration of 10 and 5mM respectively. Deiminated cell lysates were stored at -20°C.
  • Blots as prepared in example 3 were cut in strips and blocked for 2 hours at RT with 5% (w/v) low fat dry milk in PBS-Tween (wash buffer) to block all nonspecific sites. Blots were then washed 5 times 5 minutes with wash buffer and strips were incubated for an additional 1 hour at RT with 4 ml wash buffer containing 20ug anti- citrulline antibody. Thereafter, the strips were washed 5 times for 10 min with wash buffer, and incubated with a peroxydase-conjugated rabbit anti-human IgG (Dako) (1 hour at RT) in wash buffer (1 :2000). Strips where then washed 3 times for 10min with wash buffer followed by a 2 times wash with PBS to wash away all unbound antibody.
  • wash buffer 5% (w/v) low fat dry milk in PBS-Tween
  • Immunoreactive bands were visualized using chemiluminescent substrate (PIERCE), and exposed to Kodak BioMax XAR autoradiography films (Eastman Kodak Company, Rochester, NY, USA).
  • RhmAb2.102 showed reactivity with a doublet of proteins with a molecular weight of approximately 15 and 17 kiloDalton.
  • PAD4 deiminated COS-1 lysates revealed prominent p15 and p17 protein bands which could not or hardly be detected in the RhmAb 2.101 precipitates. The rate of recognition of p15 and p17 proteins therefore correlates well with the therapeutic properties of these antibodies ( Figure 1 a-d).
  • Example 6 Mass-spectrometry analysis of p15 and p17.
  • the bands at p15 and p17 of the SDS-page gels of example 3 were excised from the gel and analyzed by MALDI-TOF MS. Briefly, excised gel pieces were washed 2 times with 50 ⁇ of 25 mM ammonium bicarbonate, and incubated 30 min for each washing step. A 15 min wash was repeated as above with the addition of 30% v/v acetonitrile. All liquid was removed and 25 ⁇ of 25 mM ammonium bicarbonate + 25 ⁇ of acetonitrile added and Incubated for 15 min. Again all liquid was removed and gels were incubated 30 min with 50 ⁇ of acetonitrile. All liquid was removed and the pieces were dehydrated by incubating for 2 h at 37°C.
  • the gel pieces were allowed to swell again by adding 5 ⁇ of trypsin solution ( ⁇ 15 ng trypsin/ ⁇ in 25 mM ammonium bicarbonate/5 mM n-octyl ⁇ -D-glucopyranoside) and incubated on ice for 1 hour. Excess trypsin solution was removed and gel pieces were incubate for 14 h at 37°C with 5 ⁇ 25 mM ammonium bicarbonate/5 mM n-octyl ⁇ -D-glucopyranoside.
  • Peptides were extracted by incubating with 4 ⁇ 50% acetonitrile/0.5% trifluoroacetic acid (TFA)/5 mM n-octyl ⁇ -D-glucopyranoside for 1 h at RT. Samples were sonicated for 2 min in a sonication water bath, the liquid transferred in a new tube and the extraction step was repeated. The sample was dried in a vacuum centrifuge and subjected to MALDI-TOF MS.
  • TFA trifluoroacetic acid
  • Therapeutic anti-citrulline antibody RhmAb2.102 recognizes H2A p4.
  • Human recombinant histones H1 , H2A, H2B, H3 and H4 (10C ⁇ g) were incubated 3 hours with or without 53,4 mU huPAD2 or huPAD4 at 37°C.
  • Deiminated as well as non-deiminated histones were coated on 96-well ELISA plates (O ⁇ g /well) by overnight incubation at 4°C.
  • Wells were washed 5 times with PBS-Tween20 (PBS-T) and blocked by a 1 hour incubation with PBS-T + 1 % Bovine serum albumin (BSA) at room temperature (RT).
  • PBS-T PBS-Tween20
  • BSA Bovine serum albumin
  • RhmAb2.101 or RhmAb2.102 were incubated for 1 hour at RT with serial dilutions of RhmAb2.101 or RhmAb2.102 in PBS-T + 1 % BSA starting at a concentration of 1 C ⁇ g/well.
  • Wells were washed 5 times with PBS-T and incubated with rabbit-anti-human-HRP (1 :2000) for 1 hour at RT followed by 5 washes with PBS-T and 3 wash steps with PBS.
  • Wells incubated with RhmAb2.101 were incubated 15min and wells incubated with RhmAb2.102 were incubated 10min with TMB substrate before stopping the reaction with 2M H 2 S0 4 .
  • Optical density was measured by 450nm and is a measure for the affinity of the antibodies used.
  • Example 8 Therapeutic anti-citrulline antibody RhmAb2.102 recognizes peptide 1.
  • 96-well ELISA plates were coated with neutravidin (0,1 ⁇ g /well) by overnight incubation at 4°C. Wells were washed 5 times with PBS-Tween20 (PBS-T) and blocked by a 1 hour incubation with PBS-T + 1 % Bovine serum albumin (BSA) at room temperature (RT). After 5 more washes with PBS-T, wells were incubated for 1 hour at RT with histone derived citrulline and biotin containing peptides (0 ⁇ g /well).
  • PBS-T PBS-Tween20
  • BSA Bovine serum albumin
  • RhmAb2.101 , RhmAb2.102 or RhmAb2.104 were incubated for 1 hour at RT with serial dilutions of RhmAb2.101 , RhmAb2.102 or RhmAb2.104 in PBS-T + 1 % BSA starting at a concentration of
  • Example 9 Therapeutic anti-citrulline antibodies recognize fibrinogen and vimentin derived citrulline peptides.
  • 96-well ELISA plates were coated with neutravidin (0,1 ⁇ g /well) by overnight incubation at 4 degrees C. Wells were washed 5 times with PBS-Tween20 (PBS-T) and blocked by a 1 hour incubation with PBS-T + 1 % Bovine serum albumin (BSA) at room temperature (RT). After 5 more washes with PBS-T, wells were incubated for 1 hour at RT with fibrinogen and vimentin derived citrulline and biotin containing peptides (O ⁇ g /well).
  • PBS-T PBS-Tween20
  • BSA Bovine serum albumin
  • RhmAb2.101 or RhmAb2.102 were incubated for 1 hour at RT with serial dilutions of RhmAb2.101 or RhmAb2.102 in PBS-T + 1 % BSA starting at a concentration of 10 ⁇ g/well.
  • Wells were washed 5 times with PBS-T and incubated with rabbit-anti-human- HRP (1 :2000) for 1 hour at RT followed by 5 washes with PBS-T and 3 wash steps with PBS.
  • Wells were incubated 5min with TMB substrate before stopping the reaction with 2M H 2 S0 4 .
  • Optical density was measured by 450nm and is a measure for the affinity of the antibodies used.
  • Example 10 Therapeutic potential of RhmAb2.102
  • CAIA collagen antibody induced arthritis
  • mice/group mice For that purpose, on day 0 male DBA/J1 mice (5 mice/group) of the age of 8 weeks have been injected i.p. with a mix of 8 anti-collagen antibodies (2,8mg/mouse). On day 3, mice received another i.p. injection containing 25ug LPS. LPS triggers the inflammation. On day 7 when the mean arthritis score was around 4 ( Figure 6A) one group received an i.v. injection containing 1 mg RhmAb2.102, whether the other group received an i.v. injection containing placebo.
  • Example 1 1 Preparation of huPAD4 deiminated HEK293 extract and immunoprecipitation with RhmAb2.101 or RhmAb2.102
  • HEK293 cells were harvested, washed once with PBS, spun down, and
  • the cell samples were sonified 4 times for 15 seconds on ice.
  • the lysate was centrifuged at 3.000 rpm for 5 minutes and the supernatant transferred to a clean tube.
  • the cell lysate was deiminated for 2 hours at 37°C by adding 1 U human PAD4 per
  • IP immunoprecipitations
  • RhmAb2.101 20 ⁇ g RhmAb2.102 or not coupled (negative control).
  • Protein A Sepharose Beads / antibody mixtures have been incubated 1 h at room temperature under constant rotation. Beads were subjected to 3 washes with 1 ml IPP500, one wash with 1 ml IPP150 (10mM Tris/HCI pH8,0, 150mM NaCI, 0,1 % NP40 and 0,1 % Tween-20), and subsequently incubated at room temperature with 300 ⁇ deiminated HEK293 lysate for 2 hours under constant rotation.
  • RhmAb2.102 and control beads have been eluted with 50 ⁇ elution buffer (100mM Na citrate pH3.0) , neutralized with 10 ⁇ 1 M Tris/HCI pH9,04 and stored at -20°C until nl_C LTQ FTMS ULTRA mass spectrometry (Example 12).
  • Protein identification validation was performed by an in-house developed script. Briefly, the software classifies protein identifications based on the number of uniquely identified peptide sequences, clusters proteins sharing the same set of peptides and validates the proteins with the following criteria:
  • Proteins with 1 peptide must have a peptide score: >49
  • Proteins with more than 1 peptide must have a peptide score: >29
  • peptides have been identified in all 3 samples (sample 1 : HEK293 precipitate with RhmAb2.101 ; sample 2: HEK293 precipitate with Rhm2.102; sample 3: HEK293 precipitate with empty beads).
  • emPAI Extraly Modified Protein Abundance Index
  • gi 45031431 ref 1 N P_001900.11 cathepsin D preproprotein [Homo sapiens] ⁇ gi 775397581 ref
  • Example 13 Generation/selection of a family of anti-inflammatory antibodies
  • Human-derived scFv libraries were panned against PAD2-, or PAD4- deiminated forms of human Histon-2A, Histon-4, peptide 1 (AAASGXGKQGGK, SEQ ID NO: 21 ) and against CFC-1 peptide in a similar method as decribed in Raats et al., 2003 (Raats, J.M.H., Wijnen, E.W, Pruijn, G.J.M., Van den Hoogen, F.H.M., and W.J. van Venrooij. 2003. J. Rheum. 30, 1696-171 1 ).
  • Antibodies that immunoprecipitated bands p15 and/or p17, and/or antibodies with ELISA reactivity profiles against citrullinated epitopes PAD2 and PAD4 deiminated human Histon isoforms, and/or CFC-1 and/ or peptide 1 (AAASGXGKQGGK, SEQ ID 21 , and/or citrullinated epitopes derived from proteins listed in 9comparable with
  • RhmAb2.102 were subsequently cloned into human lgG1 format. Full size human IgG antibodies were tested for their prophylactic and/or therapeutic anti-inflammatory potential in a CAIA mouse model, as described herein.
  • This screening procedure yielded antibodies with prophylactic and or therapeutic anti inflammatory potential in the CAIA mouse model with high frequency.
  • RhmAb2.108, RhmAb2.109, RhmAb2.1 10, RhmAb2.1 1 1 and RhmAb2.1 12 are disclosed herein in SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 39, SEQ ID NO: 20, SEQ ID NO: 41 , SEQ ID NO: 40, SEQ ID NO: 19, SEQ ID NO: 43, SEQ ID NO: 42.
  • the RhmAb2.1 10 immunoglobulin light chain encoded by SEQ ID NO: 10 comprises a mouse leader globulin according to SEQ ID NO: 12, followed by the variable antibody light chain according to SEQ ID NO: 41 followed by the immunoglobulin human kappa constant domain according to SEQ ID NO: 1 1.
  • RhmAb2.1 12, and RhmAb2.102 (1 mg/mouse) and placebo were administered via i.p. injection on day 3. All animals have been scored for inflammation daily until day 10.
  • Antibodies against a synthetic citrulline containing peptide according to the invention have been raised in DBA J1 mice.
  • serum samples were taken and analyzed for a citrullin specific antigen response. All mice showed a specific antigen specific serum titre at the time points tested.
  • spleens In order to produce hybridoma cell-lines, spleens have been dissected after the last boost, splenocytes were harvested from the spleen and fused with a mouse myeloma cell-line (NS-1 ) according to ModiQuest B.V. procedures. Antibody specificity in hybridoma supernatants have been screened on cirtulline containing antigen as well as on the non-ctirullinated equivalent.
  • NS-1 mouse myeloma cell-line
  • CAIA Collagen antibody induced arthritis
  • RmmAb22.101 , RmmAb22.102 and RhmAb2.102 (6mg/mouse) and placebo were administered via i.p. injection on day 3. All animals have been scored for inflammation daily until day 10.
  • RhmAb2.102, RmmAb22.101 and RmmAb22.102 antibodies completely protected the mice against inflammation in their paws.
  • Example 15 Novel therapeutic anti-citrulline antibodies display similar recognition patterns to citrullinated epitopes compared to RhmAb 2.102.
  • RhmAb2.108, RhmAb2.109, RhmAb2.1 10, RhmAb2.1 1 1 , RhmAb2.1 12, RmmAb22.101 , and RmmAb22.102 were analysed in ELISA for their reactivity on various deiminated targets compared to RhmAb 2.102.
  • Human recombinant histones H1 , H2A, H2B, H3 and H4 (100 ⁇ g) were deiminated as described in Example 7.
  • Optical density was measured by 450nm and is a relative measure for the affinity of the antibodies used. This showed clearly that all therapeutic antibodies have a highly similar staining pattern compared to the therapeutic antibody RhmAb2.102. Only the mouse monoclonals show no reactivity with the Cfc1 - peptide. All therapeutic antibodies, have very high reactivity with the a peptide according to SEQ ID No: 21 , as well as with Histon 2A/p2 Histon 2A/p4, and histon 4/p2, and show slight reactivity with Histon 3/p2.

Abstract

This invention is in the field of treating or preventing inflammation in humans and animals and relates to pharmaceutical compositions and methods for treating or preventing various inflammatory conditions. In particular, the invention relates to compositions and methods for treating or preventing inflammatory conditions such as citrulline related inflammatory diseases. The invention provides specific binding molecules directed against citrulline-containing epitopes for use in the therapy and prevention of inflammatory conditions.

Description

ANTI-INFLAMMATORY AGENTS DIRECTED AGAINST CITRULLINATED EPITOPES
Field of the Invention
This invention is in the field of treating or preventing inflammation in humans and animals and relates to pharmaceutical compositions and methods for treating or preventing various inflammatory conditions. In particular, the invention relates to compositions and methods for preventing or treating inflammatory conditions such as citrulline related diseases, preferably inflammatory diseases, more preferably
inflammatory arthritis, such as rheumatoid arthritis. The invention provides specific binding molecules such as antibodies directed against citrulline-containing epitopes for use in the therapy and prevention of inflammatory conditions such as inflammatory arthritis, preferably rheumatoid arthritis.
Background of the invention
Inflammatory conditions, whether of a chronic or acute nature, represent a substantial problem in the healthcare industry. Briefly, chronic inflammation is considered to be inflammation of a prolonged duration (weeks or months) in which active inflammation, tissue destruction and attempts at healing are proceeding simultaneously (Robbins Pathological Basis of Disease by R. S. Cotran, V. Kumar, and S. L. Robbins, W. B. Saunders Co., p. 75, 1989). Although chronic inflammation can follow an acute inflammatory episode, it can also begin as an insidious process that progresses with time, for example, as a result of a persistent infection (e.g., tuberculosis, syphilis, fungal infection) that causes a delayed hypersensitivity reaction, prolonged exposure to endogenous (e.g., elevated plasma lipids) or exogenous (e.g., silica, asbestos, cigarette tar, surgical sutures) toxins, or autoimmune reactions against the body's own tissues (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, psoriasis).
Inflammatory arthritis is a serious health problem in developed countries, particularly given the increasing number of aged individuals. For example, one form of inflammatory arthritis, rheumatoid arthritis (RA) is a multisystem chronic, relapsing, inflammatory disease affecting 1 to 2% of the world's population.
Although many organs can be affected, RA is basically a severe form of chronic synovitis that sometimes leads to destruction and ankylosis of affected joints (Robbins Pathological Basis of Disease, by R. S. Cotran, V. Kumar, and S. L. Robbins, W.B. Saunders Co., 1989). Pathologically the disease is characterized by a marked thickening of the synovial membrane which forms villous projections that extend into the joint space, multilayering of the synoviocyte lining (synoviocyte proliferation), infiltration of the synovial membrane with white blood cells (macrophages, lymphocytes, plasma cells, and lymphoid follicles; called an "inflammatory synovitis"), and deposition of fibrin with cellular necrosis within the synovium. The tissue formed as a result of this process is called pannus and eventually the pannus grows to fill the joint space. The pannus develops an extensive network of new blood vessels through the process of angiogenesis, which is essential to the evolution of the synovitis. Release of digestive enzymes (matrix metalloproteinases (e.g., collagenase, stromelysin)), and other mediators of the inflammatory process (e.g., hydrogen peroxide, superoxides, lysosomal enzymes, and products of arachadonic acid metabolism), from the cells of the pannus tissue leads to the progressive destruction of the cartilage tissue. The pannus invades the articular cartilage leading to erosions and fragmentation of the cartilage tissue. Eventually there is erosion of the subchondral bone with fibrous ankylosis, and ultimately bony ankylosis, of the involved joint.
It is generally believed that RA is an autoimmune disease and that many different arthrogenic stimuli activate the immune response in an immunogenetically susceptible host. Both exogenous infectious agents (Epstein-Barr virus, rubella virus, cytomegalovirus, herpes virus, human T-cell lymphotropic virus, Mycoplasma, and others) and endogenous proteins such as collagen, proteoglycans, altered immunoglobulins and post-translationally modified proteins like citrullinated proteins have been implicated as a causative agent that triggers an inappropriate host immune response. Regardless of the inciting agent, autoimmunity plays a role in the progression of the disease. In particular, the relevant antigen is ingested by antigen-presenting cells (macrophages or dendritic cells in the synovial membrane), processed, and presented to T lymphocytes. The T cells initiate a cellular immune response and stimulate the proliferation and differentiation of B lymphocytes into plasma cells. The end result is the production of an excessive
inappropriate immune response directed against the host tissues (e.g., antibodies directed against type II collagen, antibodies directed against the Fc portion of autologous IgG (called "Rheumatoid Factor")), and antibodies directed against different citrullinated epitopes (anti-CCP). This further amplifies the immune response and hastens the destruction of the cartilage tissue. Once this cascade is initiated numerous mediators of cartilage destruction are responsible for the progression of rheumatoid arthritis.
The above mentioned anti-CCP antibodies have been demonstrated to be highly specific for RA. Recent evidence shows that each individual that is seropositive for these antibodies either already has RA or will develop this disease in the future. The presence of anti-CCP antibodies (especially when high titers are present) is predictive of erosive disease outcome (Nijenhuis et al., Clin. Chim. Acta, vol 350, 17-34, 2004). Furthermore, it has been demonstrated that anti-CCP antibodies are produced locally at the site of inflammation. The proportion of anti-CCP antibodies with respect to total IgG found in synovial material from RA patients appeared to be significantly higher than that in serum of the same patients (Masson-Bessiere et al, Clin Exp Immunol, vol 1 19, 544-552, 2000) (Reparon-Schuijt et al, Arthritis Rheum, vol 44, 41 -47, 2001 ).
The presence of anti-CCP producing plasma cells in the synovium is indicative of an antigen-driven maturation of CCP-specific B cells at the site of
inflammation. Once anti-CCP antibodies are produced, the formation of immune complexes with citrullinated proteins in the synovia may trigger the progression of the inflammatory process. These and other data supported the hypothesis that anti-CCP antibodies actually caused at least part of the disease symptoms of RA. A role for the anti- CCP antibodies in the pathogenesis of RA is supported by the results of B lymphocyte depletion experiments in patients with RA (Cambridge et al., Arthritis Rheum, vol48, 2146- 2154, 2003).
People with advanced rheumatoid arthritis have a mortality rate greater than some forms of cancer and because of this, treatment regimes have shifted towards aggressive early drug therapy designed to reduce the probability of irreversible joint damage. Recent recommendations of the American College of Rheumatology (Arthritis and Rheumatism 39(5)713-722, 1996) include early initiation of disease-modifying anti- rheumatic drug (DMARD) therapy for any patient with an established diagnosis and ongoing symptoms. Anticancer drugs have become the first line therapy for the vast majority of patients, with the chemotherapeutic drug methotrexate being the drug of choice for 60 to 70% of rheumatologists. The severity of the disease often warrants indefinite weekly treatment with this drug, and in those patients whose disease progresses despite methotrexate therapy (over 50% of patients), second line chemotherapeutic drugs such as cyclosporin and azathioprine (alone or in combination) are frequently employed.
There remains a need for compounds for the treatment or prevention of inflammatory diseases that are capable of inhibiting the pathogenesis of inflammatory diseases, in particular diseases wherein the synovium is involved and citrulline related inflammatory diseases.
Summary of the invention
The invention provides a binding molecule specifically reactive with a citrullinated epitope on p15 and/or p17 for use in the treatment or prevention of inflammatory diseases.
P15 and p17 are identified herein as human PAD4 and/or PAD2 deiminated human histone 2A and/or histone 4, and/or on human PAD2 deiminated human histone H3.
The invention also provides a method for treating or preventing an inflammatory disease, comprising the step of administering to a patient in need thereof a therapeutically effective amount of an anti-inflammatory composition comprising a binding molecule specifically reactive with a citrulline epitope on p15 and/or p17.
The compositions and methods of the present invention include pharmaceutically acceptable formulations of specific binding molecules reactive with citrulline residues. In particular, the binding molecules are specifically reactive with citrullinated epitopes on two polypeptides as identified herein, termed p 15 and p17.
The invention also relates to polypeptides and nucleic acids as identified herein.
These and other aspects of the present invention will become evident upon reference to the following detailed description, figures and examples. In addition, various references are set forth herein which describe in more detail certain procedures, devices, or compositions, and are therefore incorporated by reference in their entirety.
Detailed description of the invention.
The invention provides a binding molecule specifically reactive with a citrullinated epitope on p15 and/or p17 for use in the treatment or prevention of inflammatory diseases.
The term "specific binding molecule" is used herein to indicate a molecule, preferably a small molecule, capable of specific binding. Specific binding in this respect is intended to mean that the molecule is capable of binding to a selected target molecule whereas it will not bind to another non-related target molecule under the same conditions. For instance, a binding molecule is said to specifically bind to serum albumin when it binds to serum albumin and less or not at all to another or preferably any other protein found in serum. Preferred specific binding molecules are antibodies.
The term: "specifically reacts with citrulline" or "reactive with a citrullinated epitope" or "reactive with a citrulline epitope" in this context means that the specific binding molecule or antibody reacts with a structure such as a peptide containing a citrulline residue whereas the antibody reacts less or preferably not at all with the same structure containing an arginine residue instead of the citrulline residue. The term peptide should be interpreted as a structure that is capable of presenting the citrulline residue in the correct context for immunoreactivity with the specific binding molecules as described herein, preferably in the same context as it appears in the human or animal body, preferably in the context of a native polypeptide. It is also preferred that the citrullin residue is presented in the context of a native polypeptide that does not activate or trigger other components of the immune system such as cell activation or complement binding.
The "specific binding molecule" may be a molecule, preferably a small molecule composed of DNA, RNA, peptide, protein domain, whole proteins, or combinations thereof or parts thereof, that are capable of specifically binding to a target compound. Preferred examples of specific binding molecules are peptides or antibodies.
Native antibodies (also known as immunoglobulins) are gamma globulin proteins that may be found in blood or other bodily fluids of vertebrates, and are used by the immune system to identify and neutralize foreign objects, such as bacteria and viruses.
Native antibodies are typically made of basic structural units - each with two large heavy chains and two small light chains - to form, for example, monomers with one unit, dimers with two units or pentamers with five units. Antibodies are produced by a white blood cell called a B cell. There are several different types of heavy chains, resulting in different kinds of antibodies. Antibodies may be grouped into different isotypes based on which heavy chain they possess. Five different antibody isotypes are known in mammals which perform different roles, and help direct the appropriate immune response for each different type of foreign object they encounter. Some animal species such as Camelids (e.g. llamas) and sharks may have aberrant antibody structures.
Although the general structure of all antibodies is very similar, a small region at the tip of the protein is extremely variable, allowing millions of antibodies with slightly different tip structures to exist. This region is known as the hypervariable region. Each of these variants can bind to a different target, known as an antigen. This huge diversity of antibodies allows the immune system to recognize an equally wide diversity of antigens.
The unique part of the antigen recognized by an antibody is called an epitope. These epitopes bind with their antibody in a highly specific interaction that allows antibodies to identify and bind only their unique antigen in the midst of the millions of different molecules that make up an organism. Recognition of an antigen by an antibody tags it for attack by other parts of the immune system. Antibodies can also neutralize targets directly, for example, by binding to a part of a pathogen that it needs to cause an infection.
The large and diverse population of antibodies is generated by random combinations of a set of gene segments that encode different antigen binding sites (or paratopes), followed by random mutations in this area of the antibody gene, which create further diversity. Antibody genes also re-organize in a process called class switching that changes the base of the heavy chain to another, creating a different isotype of the antibody that retains the antigen specific variable region. This allows a single antibody to be used in several different isotypes by several different parts of the immune system.
The term "antibodies" or "antibody" as used herein refers to a structure, preferably a protein or polypeptide structure, capable of specific binding to a target molecule often referred to as "antigen".
An antibody may be selected from the group consisting of single chain antibodies, single Chain Variable Fragments (scFvs), Fragment antigen binding regions (Fabs), recombinant antibodies, monoclonal antibodies, fusion proteins comprising the antigen-binding domain of a native antibody or an aptamer, single domains antibodies (sdabs), also known as VHH antibodies, nanobodies (Camelids derived single domain antibodies), shark IgNAR derived single domain antibody fragments called VNAR, Anticalins, aptamers (DNA or RNA) and active components or fragments thereof,
In anotherpreferred embodiment, an antibody is a fusion protein comprising the antigen-binding domain of a native antibody or an aptamer, such as an aptamer in the form of DNA or RNA.
The term "or part thereof" or "fragments thereof" in the context of an antibody or other specific binding molecule is meant to refer to the part of the antibody or specific binding molecule that makes up the specific binding site of the antibody or specific binding molecule and may be interpreted as the part of an antibody or specific binding molecule that is still capable to react with the same epitope as the entire antibody or specific binding molecule.
Human antibodies or fragments thereof are a preferred embodiment of the invention. Preferably lgG1 (e.g., IgGIA) antibodies having an lgG1 heavy chain and a lambda light chain may advantageously be used. However, other human antibody isotypes are also encompassed by the invention, including lgG2, lgG3, lgG4, IgM, lgA1 , lgA2, IgAsec, IgD and IgE in combination with a kappa or lambda light chain. Also all animal-derived antibodies of various isotypes can be used in the invention. The antibodies can be full-size antibodies or antigen-binding fragments of antibodies, including Fab, F(ab')2, single chain Fv fragments, or single domain VHH, VH or VL single domains.
The term "specific binding molecules reactive with a citrullinated epitope" are to be interpreted as specific binding molecules that specifically react with a citrulline residue in the context of a larger structure such as a peptide or a peptide nucleic acid or an aptamer or a peptide mimicking structure.
Citrulline is an amino acid that is not incorporated into proteins during normal translation, however, it may be generated by post-translational modification of an arginine residue by peptidylarginine deiminase (PAD).
Citrullination is the posttranslational conversion of arginine residues to citrulline residues, which is catalyzed by peptidylarginine deiminase (PAD).
Peptidylarginine deiminase (PAD; EC 3.5.3.15) enzymes catalyse the conversion of arginine residues to citrulline residues in proteins. No tRNA exists for citrulline, the presence of citrulline residues in proteins is exclusively the result of post-translational modification. In mammals (humans, mice and rats) five PAD isotypes (PAD1 - PAD6; 'PAD4' and 'PAD5' are used for the same isotype), each encoded by a distinct gene, have been identified (Vossenaar et al, Bioessays 25, 1 106-1 1 18, 2003). All these enzymes rely strongly on the presence of Ca2+ for activity and are unable to convert free L-arginine into free L-citrulline. Free L-arginine can be converted to free L-citrulline by nitric oxide synthase (EC 1 .14.13.39) in eukaryotes or by arginine deiminase (EC 3.5.3.6) in bacteria. These enzymes are not Ca2+ dependent.
The most pronounced difference between the highly homologous PAD enzymes is their tissue-specific expression. In epidermis PAD1 (synonyms: PAD I, PAD type I) is involved in the citrullination of keratin filaments during the final stages of keratinocyte differentiation, which is important for the reorganization of the cornified envelope. Another site of citrullination in the epidermis is the hair follicle, which contains PAD3 (synonyms PAD III, PAD type III) and its natural substrate trichohyalin (THH). THH is a major structural protein of the inner root sheath cells and the medulla layer of the hair follicle and, to a lesser extent, of other specialized epithelia. The most recently identified PAD isotype, PAD6 (synonym: ePAD), was found in cytoplasmic sheets of mouse oocytes, which play an important role in early embryogenesis. The expression of its human orthologue was found to be restricted to ovary, testis and peripheral blood leukocytes (Chavanas et al., Gene vol 330; 19-27, 2004). Originally, this PAD isotype was designated ePAD, but based upon the systematic numbering of other PADs, this isotype was renamed PAD6 (Vossenaar et al., Bioessays vol 25 1 106-1 1 18, 2003). The most widely expressed isotype, PAD2 (synonyms PAD II, PAD type II, PAD-H19), is present in many different tissues, like skeletal muscle, brain, spleen, secretory glands and macrophages. Despite this broad expression pattern, only myelin basic protein (MBP) and vimentin have been identified as natural substrates. In multiple sclerosis (MS) patients develop an autoimmune response against MBP. MBP is an abundant protein of the myelin sheath, and its citrullination occurs during development of the central nervous system. Citrullination of vimentin was observed during calcium-ionophore induced apoptosis of human and mouse macrophages and, as described above, citrullinated vimentin was shown to be the target of the RA-specific anti-Sa autoantibodies. In contrast to the PADs discussed above, which are all mainly localized in the cytoplasm of cells, the PAD4 isotype (synonyms: PAD IV, PAD type IV, HL-60 PAD, PAD V, PAD type V, PADI4) is localized in the nucleus. The nuclear localization signal of PAD4 was found in the N- terminal region of the protein. PAD4 is mainly expressed in peripheral blood granulocytes and monocytes. Substrates of PAD4 in the nucleus are histone core proteins (H2A, H3 and H4) and nucleophosmin/B23, a nucleolar protein that functions in ribosome assembly, nucleocytoplasmic transport and centrosome duplication.
Specific binding molecules according to the invention are directed against a citrullinated epitope on p15 and/or p17, two polypeptides characterized by their molecular weights of 15 kDa and 17 kDa, respectively.
Such specific binding molecules were found to be particularly suited for the treatment or prevention of inflammatory diseases.
"Inflammatory Conditions" or Inflammatory diseases" as used herein refers to any of a number of conditions or diseases which are characterized by vascular changes: edema and infiltration of neutrophils (e.g., acute inflammatory reactions);
infiltration of tissues by mononuclear cells; tissue destruction by inflammatory cells, connective tissue cells and their cellular products; and attempts at repair by connective tissue replacement (e.g., chronic inflammatory reactions).
Representative examples of such conditions include citrulline related inflammatory diseases and autoimmune diseases. Citrulline related inflammatory diseases are herein defined as those diseases wherein citrullination plays a role in the
pathogenesis of the disease. Whether or not citrullination plays a role in the pathogenesis of the disease, may be easily determined by a skilled person using routine tests available in the art. For example, these diseases may be characterized by the presence of an abnormal level of citrullinated proteins in affected or disease related tissue. Such may be accomplished by an immunological test such as a western blot or an ELISA wherein the affected tissue is used as an antigen and citrullination of that antigen may be detected with the aid of an anti-citrullin antibody as described herein.
Alternatively, a person skilled in the art can use Proteomics applications such as mass spec, analysis to compare the level and type of citrullinaton in a diseased versus healthy tissue from affected patients.
The disease may also be characterized by the presence of an immune response against citrulline containing peptides or proteins. This may be a humoral or a cellular immune response, such as a response mediated by T-cells or B-cells. Tests for detecting anti-citrulline antibodies have been described in the art and are commercially available.
The invention therefore relates to a specific binding molecule for use in treating or preventing citrulline related inflammatory diseases.
Such diseases are for instance inflammatory arthritis, including rheumatoid arthritis and osteoarthritis, multiple sclerosis, psoriatic arthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, spondyloarthropathy, Down's syndrome, multiple system atrophy, Parkinson's disease and Lewy body dementia. The invention therefore relates to a specific binding molecule for use in treating or preventing diseases selected from the group consisting of arthritis, rheumatoid arthritis, osteoarthritis, multiple sclerosis, psoriatic arthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, spondyloarthropathy, Down's syndrome, multiple system atrophy, Parkinson's disease and Lewy body dementia.
The invention in particular relates to specific binding molecules for the treatment or prevention of autoimmune diseases, more in particular rheumatoid arthritis or osteoarthritis.
Multiple sclerosis or MS is a chronic inflammatory disorder of the CNS, characterized by autoimmunity mediated destruction of the myelin sheath. The cells of the myelin sheath form a multibilayer structure around the axons consisting of lipid-protein complexes in a ratio of about 3: 1 . Two major proteins, MBP and proteolipid protein, account for 85% of the protein fraction. MBP is a highly cationic protein, capable of forming strong interactions with negatively charged phospholipids such as
phosphatidylserine. In approximately 18% of the MBP molecules of healthy adult humans 6 (out of 19) arginines are citrullinated (Wood et al., J Biol Chem, vol264, 5121 -5127, 1989, Wood et al., Ann Neurol, vol40, 18-24, 1996). The remaining MBP molecules do not contain citrulline. In MS patients the proportion of MBP-cit6 is increased to 45% of total MBP. The decreased net positive charge of MBP-cit6 causes partial unfolding of MBP molecules and weakens their interaction with the phospholipids (Boggs et al., J Neurosci Res, vol57, 529-535, 1999, Pritzker et al., Biochemistry, vol39, 5374-5381 , 2000).
Although MBP-cit6 is capable of forming lipid complexes more rapidly than non- citrullinated MBP, the complexes that are formed are not as densely packed as those formed with non-citrullinated MBP (Boggs et al, J Neurosci Res, vol57, 529-535, 1999, Beniac et al, J Struct Biol, vol129, 80-95, 2000). MBP-cit6 is degraded 4 times more rapidly by cathepsin D than non-citrullinated MBP (Cao et al., Biochemistry, vol38, 6157- 6163, 1999). In a rare case of acute fulminating MS (Marburg type), 80% of the MBP molecules are heavily citrullinated (MBPcit18) (Wood et al., Ann Neurol, vol40, 18-24, 1996). The severely unfolded MBP-cit18 is degraded 45 times more rapidly by cathepsin D than normal MBP (Cao et al., Biochemistry, vol38, 6157-6163, 1999). Clinical trials with paclitaxel, the active component of the anti-cancer drug taxol, are in progress (O'Connor et al., Ann Neurol, vol46, 470, 1999). Low doses of paclitaxel can inhibit citrullination of MBP by PAD2 in vitro (Pritzker et al., Biochim Biophys Acta, vol1388, 154-160, 1998). Treatment with paclitaxel attenuates clinical symptoms and induces remyelination of damaged sheaths (Moscarello et al., Mult Scler, vol8, 130138, 2002), underlining the possible importance of PAD as a candidate factor in demyelinating disease (Moscarello et al., J Neurochem, vol81 , 335-343, 2002).
In psoriasis, keratinocytes proliferate very rapidly and travel from the basal layer to the surface in only about four days. The skin can not shed these cells quickly enough so they accumulate in thick, dry patches, or plaques. In normal keratinocytes, keratin K1 is citrullinated by PAD1 during terminal differentiation. This process causes the keratin filaments to become more compact, which is essential for the normal cornification process of the epidermis. The keratinocytes in the psoriatic hyperproliferative plaques do not contain citrullinated keratin K1 (Ishida-Yamamoto et al., J Invest Dermatol, vol1 14, 701 -705, 2000). It is not clear whether the increased cell proliferation prevents adequate citrullination by PAD or that inactivity of PAD allows hyperproliferation and accumulation of keratinocytes. Although the mechanism is unknown, aberrant citrullination in psoriatic epidermis obviously is related to PAD1 .
In a preferred embodiment, the composition according to the invention is in a form selected from the group consisting of an aqueous solution, a gel, a hydrogel, a film, a paste, a cream, a spray, an ointment, or a wrap. In further embodiments, the above methods are used to administer the compositions described herein by a route selected from intra-articular, intraperitoneal, topical, rectal, intravenous, oral, ocular, or to the resection margin of tumors.
In certain embodiments, a pharmaceutically acceptable carrier comprises at least one carrier selected from the group consisting of a co-solvent solution, liposomes, micelles, liquid crystals, nanocrystals, nanoparticles, emulsions,
microparticles, microspheres, nanospheres, nanocapsules, polymers or polymeric carriers, surfactants, suspending agents, complexing agents such as cyclodextrins or adsorbing molecules such as albumin, surface active particles, and chelating agents. In further embodiments, a polysaccharide comprises hyaluronic acid and derivatives thereof, dextran and derivatives thereof, cellulose and derivatives thereof (e.g., methylcellulose, hydroxy-propylcellulose, hydroxy-propylmethylcellulose, carboxymethylcellulose, cellulose acetate phthalate, cellulose acetate succinate, cellulose acetate butyrate,
hydroxypropylmethyl-cellulose phthalate), chitosan and derivative thereof, [beta]-glucan, arabinoxylans, carrageenans, pectin, glycogen, fucoidan, chondrotin, dermatan, heparan, heparin, pentosan, keratan, alginate, cyclodextrins, and salts and derivatives, including esters and sulfates, thereof.
In a further aspect, the method according to the invention comprises delivering a composition according to the invention to a target site, most notably a synovial joint.
In one specific embodiment of the present invention, the specific binding molecule competes with monoclonal antibodies RhmAb2.102, RhmAb2.108,
RhmAb2.109, RhmAb2.1 10, RhmAb2.1 1 1 and RhmAb2.1 12 and RmmAb 22.101 for binding to p15 and/or p17.
These antibodies are disclosed herein by the primary amino acid sequence of their heavy and light chains, see table 10.
Table 10
Seq. ID. Prot/DNA Name
1 prot. histone 3, h2bb [Mus musculus]
2 prot. histone 3, h2bb [Mus musculus]
3 prot. similar to histone H2B [Bos taurus]
4 prot. histone cluster 1, H2bn [Bos taurus]
5 prot. histone cluster 2, H4 [ attus norvegicus]
6 prot. histone cluster 2, H4 [Rattus norvegicus]
7 prot. histone cluster 2, H4 [Rattus norvegicus]
8 DNA human IgGl heavy chain RhmAb2.102
9 DNA human Lambda light chain RhmAb2.102
10 DNA human kappa light chain Rhmab2.110
11 DNA human kappa constant domain
12 prot. Mouse Leader sequence
13 prot. VH Rhmab2.102
14 prot. human constant Fc IgGl
15 prot. VL Rhmab2.102
16 prot. human Lambda constant domain
17 DNA VL Rhmab2.108
18 DNA VH Rhmab2.108 and Rhmab2.111
19 DNA VL Rhmab2.111
20 DNA VH Rhmab2.109
21 prot. peptide n°l (human Histone 2A)
22 prot. peptide n°2 (human Histone 2A)
23 prot. peptide n°3 (human Histone 2A)
24 prot. peptide n°4 (human Histone 2A)
25 prot. peptide n°5 (human Histone 2A) 26 prot. peptide n°6 (human Histone 2A)
27 prot. peptide n°7 (human Histone 2A)
28 prot. peptide n°8 (human Histone 2A)
29 prot. peptide n°9 (human Histone 2A)
30 prot. peptide n°10 (human Histone 2A)
31 prot. peptide n°ll (human Histone 2A)
32 prot. peptide n°12 (human Histone 2A)
33 prot. msFiba XH
34 prot. msFiba XG
35 prot. huFiba XH
36 prot. huFiba XG
37 prot. msFib XG
38 prot. msVim XS/XL
39 DNA VL hmab2.109
40 DNA VH Rhmab2.110
41 DNA VL hmab2.110
42 DNA VH Rhmab2.112
43 DNA VL Rhmab2.112
44 DNA VH Rmmab22.101
45 DNA VL Rmmab22.101
Binding molecules or antibodies competing with the monoclonal antibodies as disclosed herein may be selected by standard procedures. In short: a binding assay such as an ELISA may be developed wherein the antigens as disclosed herein are immobilized on a solid support. The monoclonal antibodies as disclosed herein may be labeled and interference with their binding to the immobilized antigens may be easily determined by routine analysis. These and other, more sophisticated methods are known to the skilled person and can routinely performed in an ordinary laboratory setting.
In particular, assays may easily be developed using any of the antigenic proteins according to SEQ ID NO: 21 , SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 37 and SEQ ID NO: 38 immobilized on a solid support. Monoclonal antibodies selected from the group consisting of RhmAb2.102, RhmAb2.108, RhmAb2.109, RhmAb2.1 10,
RhmAb2.1 1 1 RhmAb2.1 12 and RmmAb 22.101 may be labeled and contacted with the immobilized antigen in the presence and the absence of a test antibody. If the test antibody interferes with the binding, i.e. lowers the signal obtained with any of the labeled antibodies, it may be concluded that the test antibodie competes with binding of the labeled antibody. Such a competing antibody would then be suitable for use in the methods of the invention.
The invention therefore relates to an antibody for use in the treatment or prevention of rheumatoid arthritiswherein the antibody is specifically reactive with a peptide selected from the group consisting of SEQ ID NO: 21 , SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 37 and SEQ ID NO: 38.
The primary mRNA sequences of the variable regions of monoclonal antibody RhmAb2.101 have been published and were deposited in the EMBL database under accession numbers as shown in table 1 . The primary sequence of the variable regions of monoclonal antibodies RhmAb2.102, RhmAb2.108, RhmAb2.109,
RhmAb2.1 10, RhmAb2.1 1 1 and RhmAb2.1 12, are disclosed herein in SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 39, SEQ ID NO: 20, SEQ ID NO: 41 , SEQ ID NO: 40, SEQ ID NO: 19, SEQ ID NO: 43, and SEQ ID NO: 42
Mouse monoclonals RmmAb 22.101 and RmmAb 22.102, were derived from hybridomas deposited with the DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Inhoffens^e 7 B, 38124 Braunschweig, GERMANY and received DSMZ desposit number ACC 3031 and ACC 3032 respectively, After sequencing they appeared to have an identical DNA sequence which is shown in SEQ ID NO: 44 and SEQ ID NO: 45.
The invention therefore also relates to a polypeptide comprising a variable heavy or light chain selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 , SEQ ID NO: 19, SEQ ID NO: 43, SEQ ID NO: 42, SEQ ID NO: 44 and SEQ ID NO: 45.The invention also relates to a nucleic acid encoding a polypeptide selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 , SEQ ID NO: 19, SEQ ID NO: 43, SEQ ID NO: 42, SEQ ID NO: 44 and SEQ ID NO: 45. The invention also relates to a polypeptide comprising a variable heavy and light chain as is present in Rmm22.101 and RmmAb22.102.
The invention also relates to a nucleic acid encoding a polypeptide according a variable heavy and light chain as is present in RmmAb22.101 and
RmmAb22.102 which is shown in SEQ ID NO: 44 and SEQ ID NO: 45.
In another preferred embodiment, the specific binding molecule is an antibody selected from the group consisting of monoclonal antibodies RhmAb2.102, RhmAb2.108, RhmAb2.109, RhmAb2.1 10, RhmAb2.1 1 1 and RhmAb2.1 12,
RmmAb22.101 , and RmmAb22.102.
In another preferred embodiment, the specific binding molecule comprises VH and /or VL domains derived or obtained from an antibody selected from the group consisting of monoclonal antibodies and RhmAb2.102, RhmAb2.108, RhmAb2.109, RhmAb2.1 10, RhmAb2.1 1 1 and RhmAb2.1 12, RmmAb22.101 , and RmmAb22.102.
The term "derived" or "obtained" in this context means that the primary structure of the VH and/or VL domains may be determined from the protein and nucleic acid sequences disclosed herein and cloned and rearranged in a different context, for instance a human antibody context displaying a mouse VH or VL domain. More in particular, the term "derived" or "obtained"in this respect means that the essential residues responsible for the specific binding properties of the VH and /or VL domains in a particular antibody are identified and that these essential residues or structural homologues thereof are then transferred into the context of another peptide.
Specific binding molecules according to the invention may be generated essentially in two ways. First, they may be derived from the antibodies and its sequences as presented herein. Reactivity of the antibodies may even be improved by side-directed mutagenesis, chain shuffling, sexual PCR, or by other means for antibody derivation and optimisation known to the person skilled in the art. Alternatively, specific binding molecules, in particular antibodies may be obtained by panning with any of the specifically reactive epitopes as described herein, in particular deiminated Histon 2A, peptide 1 (SEQ ID NO: 21 ) and other particularly reactive peptides.
A person skilled in the art may use the sequences described herein to clone or generate cDNA or genomic sequences for instance such as described in the below examples. Cloning of these sequences in an appropriate eukaryotic expression vector, like pcDNA3 (In Vitrogen), or derivates thereof, and subsequent transfection of mammalian cells (like CHO cells) with combinations of the appropriate light chain and heavy chain containing vectors will result in the expression and secretion of the listed antibodies RhmAb2.102, RhmAb2.108, RhmAb2.109, RhmAb2.1 10, RhmAb2.1 1 1 and RhmAb2.1 12, RmmAb22.101 , and RmmAb22.102. Also, mouse monoclonals
RmmAb22.101 and RmmAb22.102 may be directly expressed and secreted by their respective hybridoma cell lines as deposited. (DSMZ numbers ACC 3031 and ACC 3032)
The skilled person may also make analogues of the specific binding molecules as described herein by using the specific binding domains of the antibody sequences and express them in a different context such as a polypeptide such as a fusion protein. This is well known in the art.
Recombinant Human and Mouse monoclonal anti-citrulline antibodies were obtained as described in Examples 1 , 13, and 14. Monoclonal antibody heavy chains RhmAb2.102, RhmAb2.108, RhmAb2.109, RhmAb2.1 10, RhmAb2.1 1 1 and RhmAb2.1 12 were obtained with a mouse leader sequence (SEQ ID NO: 12), and a human lgG1 Fc region (SEQ ID NO: 14). Monoclonal antibody light chains RhmAb2.102, RhmAb2.108, RhmAb2.109, RhmAb2.1 1 1 and RhmAb2.1 12 were obtained with a mouse leader sequence (SEQ ID NO: 12) and a human Lambda constant region (SEQ ID NO: 16). Monoclonal antibody RhmAb2.1 10 was obtained with a mouse leader sequence (SEQ ID NO: 12) and a human Kappa constant region (SEQ ID NO: 1 1 ).
Mouse monoclonal anti-citrullin-peptide antibodies RmmAb13.101 , RmmAb13.102 and RmmAb13.103 were obtained from a commercial source (ModiQuest Research BV Nijmegen, The Netherlands; Cat no, MQ13.101 , MQ13.102and MQ13.103).
Anti-citrullin antibodies were tested in an experimental model wherein inflammation is induced by injecting anti-collagen antibodies into a mouse. This model is known as collagen antibody induced arthritis (CAIA) (Nandakumar and Holmdahl, J Immunol Methods, vol304, 126-136, 2005). Anti collagen antibodies were obtained from a commercial source (ModiQuest Research BV Nijmegen, The Netherlands; Cat no, MQ18.101 ).
Mouse monoclonal anti-citrulline antibodies RmmAb13.101 ,
RmmAb13.102 and RmmAb13.103 were confirmed to enhance the severity of the collagen antibody induced arthritis, as has been described also by Kuhn et al. (J. Clin. Invest, vol1 16, 961 -871 , 2006); and Hill et al. (J Exp Med, vol 205, 967-979, 2008). This is shown in figures 1 a and 1 b.
Furthermore, several studies in human patients indicate that antibodies against citrullinated epitopes add to the pathogenesis of RA (Masson-Bessiere et al, J. Immunol, vol166, 4177-4184, 2001 ; Vossenaar and van Venrooij, Arthritis Res Ther, vol6, 107-1 1 1 , 2004). This is shown in Figure 1 a and b, which shows the "mean arthritis score" and "arthritis incidence" respectively of the same experiment.
Surprisingly, however, human monoclonal antibody RhmAb2.102 dramatically reduced the clinical signs of arthritis in the experimental CAIA model.
Results obtained with RhmAb2.102 are shown in Figures 1 c and 1 d. Results obtained with RhmAb2.108, RhmAb2.109, RhmAb2.1 10, RhmAb2.1 1 1 and RhmAb2.1 12 were even better as compared to RhmAb2.102, as shown in Figure 9.
The human monoclonal antibody RhmAb2.101 had no effect at all on the clinical signs of arthritis at the dose applied. The commercially available antibody RhmAb2.201 is used as an irrelevant antibody control in this experiment (ModiQuest Research B.V., cat no: MQR2.201 ). This antibody does not recognize citrulinated epitopes.
The same animal experiments were also performed with the mouse monoclonal antibodies RmmAb22.101 , and RmmAb22.102 which recognize a similar subset of epitopes as the human antibodies RhmAb2.108, RhmAb2.109, RhmAb2.1 10, RhmAb2.1 1 1 and RhmAb2.1 12.
Similar results were obtained in the CAIA animal experiments as with the human antibodies RhmAb2.108, RhmAb2.109, RhmAb2.H 0, RhmAb2.1 1 1 and RhmAb2.1 12. The Mouse monoclonals RmmAb22.101 and RmmAb22.102 abolished the clinical signs of arthritis. (Figure 10)
Figure 1 e and 1f show an independent CAIA experiment in which the clinical dose for RhmAb2.102 has been evaluated. The lowest dose that gave maximum inhibition was 0,5 mg Ab/mouse which corresponds to 28 mg/kg at IP injection.
From these experiments it is concluded that the specific epitopes recognized by monoclonal antibodies selected from the group consisting RhmAb2.102, RhmAb2.108, RhmAb2.109, RhmAb2.1 10, RhmAb2.1 1 1 and RhmAb2.1 12,
RmmAb22.101 , and RmmAb22.102 play an important role in the treatment or prevention of inflammatory diseases. Specific masking of these epitopes may therefore be an effective therapy of inflammatory diseases, in particular rheumatoid arthritis.
In order to further analyze the antigen or antigens recognized by these monoclonal antibodies, they were tested for their reactivity towards cell extracts that were deiminated using Peptidylarginine deiminase (PAD enzyme) as described in Example 3. Western blots containing hPAD2 or hPAD4 transfected COS-1 lysates that were post- lytically deiminated were incubated with the monoclonal antibodies RhmAb2.101 and RhmAb2.102. It was observed, that only strips incubated with RhmAb2.102 showed reactivity with a doublet of proteins with a molecular weight of approximately 15 and 17 kiloDalton.
WO 2004/078098 discloses antibodies specific for citrullinated peptide/MHC class II complexes to inhibit T cell activation. These antibodies do not bind to the separate peptide or MHC class II molecule but only to the complex of the peptide and the MHC class II molecule. The antibodies disclosed herein are different from the antibodies disclosed in WO 2004/078098 since they recognize the individual peptides and proteins as disclosed herein. Moreover, the antibodies recognize a polypeptide in a western blot that could not be a complex between a peptide and an MHC class II molecule, since the complex between an MHC molecule and a citrullinated peptide would never survive the reducing conditions of an SDS gel used in the immunoblot procedure. The epitopes recognized by the binding molecules as disclosed herein are therefore different from the antibodies disclosed in WO 2004/078098. Moreover, the antibodies as disclosed herein are not specifically reactive with a complex of a peptide and an MHC class II molecule.
The above described experiments and considerations led us to conclude that there is a clear correlation between the ability to prevent clinical signs of inflammatory diseases and reactivity with citrullinated epitopes on p15 and p17. Similar data were obtained when human monoclonal antibodies RhmAb2.101 , and RhmAb2.102 were used in immunoprecipitation experiments as detailed in Example 5.
Immunoprecipitations with RhmAb2.102, on both human PAD2 and PAD4 deiminated COS-1 lysates revealed prominent p15 and p17 protein bands.
The intensity of recognition of p15 and p17 proteins therefore seems to correlate well with the therapeutic properties of these antibodies (Figures 1 a-d).
Whether or not an antibody is reactive with p15 or p17 may easily be established by performing immunoprecipitation or western blot analysis as detailed in Examples 4 and 5. Alternatively, competition experiments with RhmAb2.102,
RhmAb2.108, RhmAb2.109, RhmAb2.1 10, RhmAb2.1 1 1 and RhmAb2.1 12,
RmmAb22.101 , and RmmAb22.102, may be performed using either Western blots containing deiminated COS-1 lysates or purified deiminated p15 and/or p17 proteins in Western blot or ELISA.
Proteins p15 and p17 were further characterized by Matrix-assisted laser desorption/ionisation-time of flight mass spectrometry (MALDI-TOF MS) as detailed in example 6. Since the genome of the African Green Monkey is not completely sequenced we screened all other mammal genome databases for homology with the peptides found with MALDI-TOF MS. Proteins found with a high degree of homology turned out to be histones. This is shown in Table 3 (Example 6).
The invention therefore also relates to a binding molecule specifically reactive with a citrullinated epitope on histones for use in the treatment or prevention of inflammatory diseases.
The citrullination of histones by enzymatic action of PAD is well documented and therefore citrullinated histones may very well be produced in vitro. These citrullinated histones may then be used as a substrate in an enzymatic binding assay to screen and select for other specific binding molecules such as peptides and antibodies reactive with epitopes on citrullinated p15 and p17, i.e. histones. Preferably, specific binding molecules are selected that compete with antibodies RhmAb2.102, RhmAb2.108, RhmAb2.109, RhmAb2.1 10, RhmAb2.1 1 1 and RhmAb2.1 12,
RmmAb22.101 , and RmmAb22.102 for binding to p15 and/or p17.
In this document and in its claims, the verb "to comprise" and its conjugations is used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded. In addition, reference to an element by the indefinite article "a" or "an" does not exclude the possibility that more than one of the element is present, unless the context clearly requires that there be one and only one of the elements. The indefinite article "a" or "an" thus usually means "at least one".
In order to further analyze which deiminated histone or histones are involved in the therapeutic action of RhmAb2.102, RhmAb2.108, RhmAb2.109, RhmAb2.H 0, RhmAb2.1 1 1 and RhmAb2.1 12, RmmAb22.101 , and RmmAb22.102, commercial available histones (H1 , H2A, H2B, H3 and H4) were deiminated with human
peptidylarginine deiminase (PAD, EC 3.5.3.15) enzymes (huPAD2 or huPAD4).
Deiminated as well as non-deiminated histones were coated on 96-well ELISA plates and incubated with serial dilutions of RhmAb2.101 and RhmAb2.102, . The results are shown in table 6 and Figure 2.
It is evident from the results shown in figure 2 that deiminated histone 2A, Histon 3, and Histon 4 are recognized by the therapeutic antibody RhmAb2.102,but not, or with significantly lower affinity by RhmAb2.101 (Figure 2a, 2b).
Furthermore, these results show that this difference in affinity between RhmAb 2.102 and RhmAb 2.101 is highest for Human PAD2 and/or PAD4 deiminated H2A, Human PAD 2 deiminated Histon 3, and Human PAD 4 and/or PAD 2 deiminated Histon 4.
These data correlate well with the effect of these antibodies on the clinical signs of arthritis in the experimental CAIA model, in which RhmAb2.102 abolishes the clinical signs of arthritis, whereas RhmAb2.101 has no effect on the clinical signs of arthritis (Figure 1 c and 1 d).
We have therefore shown that a deiminated epitope on H2A p4 and H2A p2 or its structural mimics play a crucial role in the RA inflammatory cascade. The same is true for deiminated epitopes on H3/p2, H4/p2 and H4/p4 since RhmAb2.102 shows higher affinity for these histones as compared to RhmAb2.101 (Figure 2a, 2b).
A mimic is for instance a molecule with an acceptable level of equivalent activity, which, in this case, would include as being recognized with higher affinity by RhmAb2.102 as compared to RhmAb2.101 .)
The invention therefore relates to a specific binding molecule as described above, reactive with a citrullinated epitope on human PAD4 or Human PAD 2 deiminated human histone 2A or histone 4, or on human PAD2 deiminated histone H3.
To further pinpoint the exact citrullinated epitope on H2A which is recognized by RhmAb2.102, biotin labeled peptides as shown in table 4 were synthesized containing potential deimination sites of histone 2A. These peptides were coated on 96-well neutravidin-ELISA plates and incubated with serial dilutions of RhmAb2.101 and
RhmAb2.102. The results are shown in Figure 3. Table 6A Reactivity of deiminated histones with RhmAb2.101 , shown in figure 2A
Figure imgf000020_0001
Table 6B Reactivity of deiminated histones with RhmAb2.102, shown in figure 2B
Figure imgf000021_0001
Table 7 Reactivity of selected peptides with mAbs RhmAb2.102 and RhmAb2.101 as indicated.
Figure imgf000022_0001
Table 8 Reactivity of selected peptides with mAbs RhmAb2.102 and RhmAb2.101 as indicated.
Figure imgf000023_0001
It was observed that peptide 1 (AAASGXGKQGGK, SEQ ID NO: 21 ) was recognized by the therapeutic antibody RhmAb2.102 but not by RhmAb2.101 (Table 4 and Figure 3a, 3b). The same holds true for the deiminated epitopes on peptides 4 and 6 (Table 4) since RhmAb2.102 shows higher affinity for these peptides than RhmAb2.101 (Figures 3a, 3b). We have therewith shown that the deiminated epitope or the structural equivalents or mimics thereof on peptides 1 , 4 and 6 play a crucial role in the RA inflammatory cascade. This antibody recognition pattern is very similar to the recognition pattern of H2A p4 and H2A p2. We therefore conclude that the specific binding molecules according to the invention may also be defined by their reactivity towards peptides 1 , 4 and 6; SEQ ID NO: 21 , SEQ ID NO: 24 and SEQ ID NO: 26 respectively. Each of these citrulline containing peptides or derivatives thereof, individually, or a combination of such peptides, or structures containing on or more of such peptide sequences, may be used to generate specific binding molecules such as antibodies according to the invention. Such antibodies may then be selected towards any of the other antigens as disclosed herein for optimal reactivity.
Table 4: Histone 2A citrulline containing peptides
Figure imgf000024_0001
X denote a citrulline residue
Biotin labeled and citrullin containing fibrinogen and vimentin peptides (Table 5) were also tested for reactivity with the therapeutic antibodies. Peptides were coated on 96-well neutravidin-ELISA plates. Subsequently serial dilutions of RhmAb2.101 ,
RhmAb2.102 were applied to the coated plates. The results are shown in Table 8 and Figure 4.
Table 5: Fibrinogen and vimentin citrulline containing peptides
Figure imgf000025_0001
X = citrulline
It was observed that the mouse fibrinogen β peptide (SEQ ID NO: 37) is recognized by RhmAb2.101 and RhmAb2.102 (Figure 4a,). Again RhmAb2.102 showed higher affinity compared to RhmAb2.101 (Figure 4a, 4b). Furthermore only RhmAb2.102 recognized the mouse vimentine peptide (example 9). It is very likely that besides the above mentioned peptides, also the deiminated epitopes on peptide msFib3 (SEQ ID NO: 37) and msVim (SEQ ID NO: 38) play a crucial role in the RA inflammatory cascade. However, it is therewith not excluded that also other epitopes on fibrinogen and vimentin play a role in the anti-inflammatory effects of our therapeutic antibodies.
The invention therefore also relates to a specific binding molecule as described above which is specifically reactive with an epitope on peptides msFib3 or msVim (SEQ ID NO: 37 or SEQ ID NO: 38) and their use.
In addition we have shown that citrullinated epitopes appear de novo in inflammated tissue. In an experimental mouse model for rheumatoid arthritis we were able to show that citrullinated peptides were immunoprecipitable from the inflammated forepaws of affected mice using human monoclonal antibody 102 (RhmAb2.102).
A typical CAIA experiment was therefore performed in which mice (3 mice per group) have been injected i.p. with a mix of 8 anti-collagen antibodies (2.8mg/mouse) on day 0. Three days later mice received another i.p. injection containing 25ug LPS. Scoring has been performed as described above. During this experiment each day a group of mice has been sacrificed, and paws were analyzed for citrulline presence by Western Blot analysis and Immunohistochemical techniques.
For each group of mice, forepaws were pooled and extracts made.
Immuniprecipitations (IP) have been performed on these extracts using 20 microgram RhmAb2.102 per IP. Precipitates have been subjected to SDS-page electrophoreses and transferred to a nitrocellulose membrane by Western Blot techniques. The blot was first stained with Ponceau S for total protein detection. Ponceau S staining is performed to verify that for each IP the same amount of antibody has been used. Pronounced antibody heavy and light chains could be observed in the same amounts.
Subsequently the citrulline residues present on blot have been chemically modified according to Senshu et al. (Senshu et al, Anal Biochem, vol 203, 94-100, 1992). The chemical modification can then be visualized using an antibody that recognizes the chemical modification of citrulline residues (Senshu et al, Anal Biochem, vol 203, 94-100, 1992). Deiminated fibrinogen was used as a positive control in this experiment. An immunoprecipitation without extracts was used as a negative control in these
experiments.
As from day 4, pronounced bands appeared on the blots at positions corresponding to proteins with molecular weights of 50, 15 and 17 kiloDaltons. These bands became more pronounced in day 5 and were most intense at day 6.
The arthritis incidence of the experiment was 100%, with mice having regular arthritis scores, reaching 5+ at day 6 (Fig. 5A and 5B). The amount of precipitated protein increases in time, which is visible from day 4 to 6. Based on the citrulline specificity of RhmAb2.102 and the presence of the signals on blot obtained with the anti-chemically modified citrulline antibody, we can conclude that mice subjected to CAIA have detectable citrulline levels in their inflamed joints.
In the CAIA experiments described above, anti-citrulline antibodies were injected on day 3 after anti-collagen antibody injection, when inflammation in the paws of mice was still absent or very low. This prevented the occurrence of clinical symptoms and is therefore useful as a treatment of inflation, in particular a prophylactic treatment.
We therefore wanted to study if RhmAb2.102 could also cure clinical symptoms once they had occurred. This was done by treating animals on day 7 after anti- collagen injection when mean arthritis scores of all 4 paws of all mice reached the arbitrary score of approximately 4. As is shown in figure 6A and 6B, RhmAb2.102 does not abolish the swelling observed, but rather stabilized the present inflammation/swelling. Animals were followed for 35 days after which inflammatory scores among placebo and RhmAb2.102 treated mice were equal (Figure 6B and example 10). Figure 6A shows the Mean arthritis score of all paws of each group, while Figure 6B shows the mean arthritis score of the right hind paws of the animals that have been used for histological analysis at day 35.
Histology on right hind paws of all animals has been performed in order to investigate whether RhmAb2.102 treatment on day 7 could protect the mice from permanent joint damage (Figure 7). Figure 7A shows that macroscopical inflammation in the right hind paws between experimental groups on day 35 of the experiment were similar. Most surprisingly however, all known parameters for joint erosion were decreased. When scoring Inflammatory cell influx (D), Cartilage erosion (B), Cartilage PG depletion (E), Chondrocyte death (F) and Bone erosion (C) a dramatic decrease is observed in the experimental group that has been treated on day 7 with RhmAb2.102, Indicating that RhmAb2.102 has a strong therapeutic potential in regard to preventing joint damage during inflammation (example 10). The invention therefore relates to a method for preventing or treating joint damage by administering a binding molecule as described herein to a patient in need of such a treatment.
Further CAIA experiments have been performed to investigate the therapeutic effect of RhmAb2.102 treatment on day 5, 6 and 7 respectively (Figure 8). In this experiment RhmAb2.102 has been injected i.v. in order to deliver the antibody rapidly to sites of inflammation. In this experiment prophylactic treatment at day 3, and a non treated control group have been included. Experimental procedures have been performed as in Example 10 with the only difference of injections with 1 mg RhmAb2.102 per mouse on day 3, 5 and 6. As expected RhmAb2.102 at day 3 inhibited the inflammatory response. Treating mice with i.v. injections of RhmAb2.102 on day 5, 6 or 7 stabilized the inflammation (Figure 8) as also seen in Figure 6. It is noteworthy that the signs of inflammation were not reduced whereas all parameters for joint erosion were decreased. This shows that joint erosion and inflammation are two separate entities that may be treated separately.
Additional deiminated proteins that preferentially bind to RhmAb2.102 have been identified by mass spectrometry analysis. Furthermore, deiminated proteins that preferentially bind to RhmAb2.102 and not, or with to a lesser extent to RhmAb2.101 have also been identified by additional mass spectrometry analysis. Human PAD4 deiminated Human Embryonic Kidney cell (HEK293) lysates have been immunoprecipitated with RhmAb2.101 or RhmAb2.102 (Example 1 1 ) and subjected to a high throughput nano-LC system coupled to an advanced, high-performance LTQ Fourier Transform Ion Cyclotron Resonance Mass spectrometer (nl_C LTQ FTMS ULTRA) (Example 12). Its ultra-high mass resolution, mass accuracy and sensitivity in combination with Exponentially Modified Protein Abundace Index (emPAI) calculations enabled us to identify deiminated proteins that (preferentially) bind to RhmAb2.102. This is shown in Table 7 (Example 1 1 and 12).
Hence, the invention also relates to a binding molecule specifically reactive with any of the proteins or polypeptides as shown in table 7 for use in the prevention or treatment of an inflammatory disease.
In summary, we have shown herein that a binding molecule specifically reactive with an epitope on a molecule selected from the group consisting of p15, p17, more in particular a citrullinated epitope on human PAD4 and/or PAD2deiminated human histone 2A, a citrullinated epitope on human PAD4 deiminated human histone 4, human PAD2 deiminated human histone H4, human PAD2 deiminated human histone H3, or a protein selected from the group consisting of the proteins of table 9 and even more in particular a peptide according to SEQ ID NO: 21 , SEQ ID NO: 24, SEQ ID NO 26, SEQ ID NO: 37 and SEQ ID NO: 38 may be used in the treatment or prevention of inflammatory diseases as specified herein. Whether a given binding molecule is specifically reactive with the above mentioned molecules, may easily be determined by analysis of the ability of the binding molecule to compete with an antibody selected from the group consisting of RhmAb2.102, RhmAb2.108, RhmAb2.109, RhmAb2.1 10, RhmAb2.1 1 1 and RhmAb2.1 12, RmmAb22.101 , and RmmAb22.102 for binding to an epitope on p15 or p17 or any of the citrullinated epitopes mentioned above.
Having shown the efficacy of the binding composition according to the invention, it will now be evident for the skilled person that inflammatory diseases may also be treated or prevented by eliciting an immune response wherein specific binding molecules according to the invention are generated in the patient's own body (in vivo). Such an immune response may be generated to prevent inflammatory disease from occurring (prophylaxis, prophylactic vaccines) or to ameliorate or decrease the
consequences of an inflammatory disease, i.e. therapy.
Hence, the invention also relates to a method for the prevention or treatment of inflammatory diseases by eliciting an immune response in vivo wherein specific binding molecules are generated reactive with an epitope selected from the group consisting of a citrullinated epitope on p15, p17, a citrullinated epitope on human PAD4 and/or PAD 2 deiminated human histone 2A, human PAD4 and/or PAD 2 deiminated human histone 4, human PAD2 deiminated human histone H3, and a peptide according to SEQ ID NO: 21 , SEQ ID NO: 24, SEQ ID NO 26, SEQ ID NO: 37 and SEQ ID NO: 38
Vaccines or therapeutics according to the invention may effectively comprise a citrullinated epitope specifically reactive with a binding molecule according to the invention. More in particular, the citrullinated epitope may be a citrullinated epitope on human PAD4 and/or PAD 2 deiminated human histone 2A, human PAD4 and/or PAD 2 deiminated human histone 4, human PAD2 deiminated human histone H3, or a peptide selected from the group consisting of SEQ ID NO: 21 , SEQ ID NO: 24, SEQ ID NO 26, SEQ ID NO: 37 and SEQ ID NO: 38.
Accordingly, a number of citrulline related inflammatory diseases may be treated or prevented. Hence, the invention also relates to a method as described above wherein the inflammatory disease is selected from the group consisting of autoimmune diseases, arthritis, rheumatoid arthritis, osteoarthritis, multiple sclerosis, psoriatic arthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, spondyloarthropathy, Down's syndrome, multiple system atrophy, Parkinson's disease and Lewy body dementia. Particlularly preferred is the prevention or treatment of autoimmune diseases such as rheumatoid arthritis.
Since this embodiment of the invention relates to an in vivo immune response, a preferred specific binding molecule is an antibody.
The skilled person will be aware of the fact that it is advantageous to use antibodies in the present invention that do not or not completely acyivate the immune system, such as T-cell activation or complement activation. It is therefore preferred to use an Fc portion of a human lgG4 or lgG2 when the invention is to be practiced in humans.
The peptides and proteins as mentioned herein may also be used as antigens for the detection of specific antibodies in order to diagnose inflammatory diseases, more preferably Rheumatoid Arthritis.
LEGENDS TO THE FIGURES
Figure 1 : A Collagen antibody induced arthritis (CAIA) model was used to test the effect of monoclonal antibodies on the severity of symptoms of arthritis. Mean arthritis score (Figures 1 a, 1 c and 1 e) and arthritis incidence (figures 1 b, 1 d and 1f) are indicated.
Groups of 5-6 mice were treated at day 0 through i.p. injection with anti-collagen antibodies. Mice used in the experiments shown in figure 1 a and 1 b received 1 ,6 mg anti- collagen antibody mix, whereas mice used in figure 1 c-f received 2,4 mg. LPS (25 μg mouse) together with anti-citrulline or a control antibody (RhmAb2.201 ) were administered on day 3 through i.p. injection. All antibodies were administered at
1 mg/mouse unless otherwise stated in the graph. Animals have been scored daily until day 13.
Figure 2: An enzyme linked immunosorbend assay (ELISA) was used to test the affinity of a) RhmAb2.101 and b) RhmAb2.102 for human recombinant histones (H1 , H2A, H2B, H3 and H4) deiminated with huPAD2 or huPAD4. Deiminated as well as non-deiminated histones were immobilized on 96-well ELISA plates (O^g/well). CFC-1 and CFC-0 were coated at the same concentration and served as positive and negative controls respectively for specific anti-citrulline reactivity and as coating controls. Non coated wells were used to test for aspecific binding of the antibodies. Coated wells were incubated with antibody dilution series ranging from 10ug/well down to 0,000128ug/well for 1 h at RT (z- axis). Detection of bound anti-citrulline antibodies was performed by incubating the wells with rabbit-anti-human-HRP (1 :2000) for 1 hour at RT followed by incubation with TMB substrate. The resulting OD (y-axis) is a measure for antibody binding. H1 recombinant Histon 1 ; H1/p2= huPAD2 recombinant Histon 1 ; H1/p4= huPAD4 recombinant Histon 1 and so forth (x-axis).
Figure 3: An enzyme linked immunosorbend assay (ELISA) was used to test the affinity of a) RhmAb2.101 and b) RhmAb2.102 for citrulline containing peptides derived from human histones H2A. Biotin and citrulline containing peptides derived from histone 2A were immobilized on neutravidin coated 96-well ELISA plates (0^g/well). CFC-1 and CFC-0 were coated at the same concentration and served as positive and negative controls respectively for specific anti-citrulline reactivity and as coating controls. Non coated wells were used to test for aspecific binding of the antibodies. Coated wells were incubated with antibody dilution series ranging from 10ug/well down to 0,000128ug/well for 1 h at RT (z- axis). Detection of bound anti-citrulline antibodies was performed by incubating the wells with rabbit-anti-human-HRP (1 :2000) for 1 hour at RT followed by incubation with TMB substrate. The resulting OD (y-axis) is a measure for antibody binding. Figure 4: An enzyme linked immunosorbend assay (ELISA) was used to test the affinity of a) RhmAb2.101 and b) RhmAb2.102 for citrulline containing peptides derived from fibrinogen and vimentin. Biotin and citrulline containing peptides derived from fibrinogen and vimentin were immobilized on neutravidin coated 96-well ELISA plates (0^g/well). CFC-1 and CFC-0 were coated at the same concentration and served as positive and negative controls respectively for specific anti-citrulline reactivity and as coating controls. Non coated wells were used to test for aspecific binding of the antibodies. Coated wells were incubated with antibody dilution series ranging from 10ug/well down to
0,000128ug/well for 1 h at RT (z-axis). Detection of bound anti-citrulline antibodies was performed by incubating the wells with rabbit-anti-human-HRP (1 :2000) for 1 hour at RT followed by incubation with TMB substrate. The resulting OD (y-axis) is a measure for antibody binding. Figure 5: A Collagen antibody induced arthritis (CAIA) model was used to investigate citrulline appearance in the paws. Groups of 3 mice were treated at day 0 with 2.8mg anti- collagen antibodies through i.p. injection, followed by an additional i.p. injection with LPS (25 μg mouse) on day 3. Mean arthritis score and arthritis incidence are shown in Figure 5A and 5B respectively.
Figure 6: A Collagen antibody induced arthritis (CAIA) model was used to test the therapeutic effect of RhmAb2.102 when given on day 7 after anti-collagen antibody injection. Mean arthritis score of all paws (Figure 6A) and Mean arthritis score of the right hind paws (Figure 6B) are indicated. Groups of 5 mice were treated at day 0 through i.p. injection with 2,8mg anti-collagen antibodies. LPS (25 μg mouse) was administered on day 3 through i.p. injection, and RhmAb2.102 (1 mg/mouse) or placebo were injected via the same route at day 7. Animals have been scored daily until day 35. It was observed that RhmAb2.102 at least stabilized the present inflammation.
Figure 7: Histological analysis has been performed on Haematoxylin/eosin and safranin O stained tissue slides of right hind paws of all CAIA animals that have been treated on day 7 with RhmAb2.102 or placebo (Figure 7). The following parameters have been scored (arbitrary scale of 0-3) on the stained tissue slides: Cartilage erosion (B), Bone erosion (C), Inflammatory cell influx (D), Cartilage PG depletion (E), and Chondrocyte death (F). Figure 7A shows the macroscopical inflammation in the right hind paws between experimental groups on the last day of the experiment (day 35). Each dot depicts a single animal. The horizontal lines indicate the mean score within an experimental group. It may be concluded that RhmAb2.102 injection protects the mice from permanent joint damage.
Figure 8: A Collagen antibody induced arthritis (CAIA) model was used to test the therapeutic effect of RhmAb2.102 when given on day 3, 5, 6 and 7 days after injection of anti-collagen antibodies. Groups of 5 mice were treated at day 0 through i.p. injection with 2,8mg anti-collagen antibodies. LPS (25 μg/mouse) was administered on day 3 through i.p. injection. RhmAb2.102 (1 mg/mouse) was injected i.v. at day 3, 5, 6 or 7. Animals have been scored daily until day 19. The graph depicts Mean arthritis score for each experimental group. It may again be concluded that RhmAb2.102 at least stabilized the inflammation at a level comparable to the level at the start of the therapy. Diamonds: control, Cirkel: Day 7, Open Cirkel: Day 6, Square: Day 5 and Triangle: Day 3 Figure 9: The Collagen antibody induced arthritis (CAIA) model was used to test the anti inflammatory effect of RhmAb2.102, RhmAb2.108, RhmAb2.109, RhmAb2.H 0,
RhmAb2.1 1 1 and RhmAb2.1 12 when given on day 3 after injection of anti-collagen antibodies. Mean arthritis score of all paws are indicated. Groups of 3 mice were treated at day 0 with i.p. injection of 2,8mg anti-collagen antibodies. LPS (25 μg mouse) was administered at day 3 via i.p. injection, and RhmAb2.102, RhmAb2.108,
RhmAb2.109, RhmAb2.1 10, RhmAb2.1 1 1 and RhmAb2.1 12 (1 mg/mouse) or placebo were injected via i.v. injection on the same day. Animals have been scored daily until day 14.
All new antibodies RhmAb2.108, RhmAb2.109, RhmAb2.1 10, RhmAb2.1 1 1 and
RhmAb2.1 12, showed a higher anti-inflammatory effect than RhmAb2.102.
Figure 10: The Collagen antibody induced arthritis (CAIA) model was used to test the anti inflammatory effect of RhmAb2.102, RmmAb22.101 , and RmmAb22.102 antibodies.
Groups of 3 mice were treated at day 0 with i.p. injection of 2,8mg anti-collagen antibodies. LPS (25 g/mouse) as well as RhmAb2.102, RmmAb22.101 and
RmmAb22.102 (6mg/mouse) and placebo were administered via i.p. injection on day 3. All animals have been scored for inflammation daily until day 10.
All tested antibodies, RhmAb2.102, RmmAb22.101 and RmmAb22.102, protected the mice against inflammation in their paws. Only data of RhmAb2.102 and RmmAb22.101 are shown.
Figure 1 1 : An enzyme linked immunosorbend assay (ELISA) was used to test the affinity of A) RhmAb2.102, B) RhmAb2.108, C) RhmAb2.109, D) RhmAb2.1 10, E) RhmAb2.1 1 1 , F) RhmAb 2.1 12, G) RmmAb22.101 , and H) RmmAb22.102 for human recombinant histones (H1 , H2A, H2B, H3 and H4) deiminated with huPAD2 or huPAD4. Deiminated as well as non-deiminated histones, and BSA were immobilized on 96-well ELISA plates (0,3 g/well). CFC-1 , CFC-0, SEQ ID NO: 21 were coated at the same concentration and served as positive and negative controls respectively for specific anti-citrulline reactivity and as coating controls. Non coated wells were used to test for aspecific binding of the antibodies. Coated wells were incubated with antibody dilution series ranging from 2,5 ug/well down to 0,004ug/well for 1 h at RT (z-axis). Detection of bound anti-citrulline antibodies was performed by incubating the wells with rabbit-anti-human-HRP (1 :2000) for 1 hour at RT followed by incubation with TMB substrate. The resulting OD (y-axis) is a measure for antibody binding. H1 recombinant Histon 1 ; H1/p2= huPAD2 recombinant Histon 1 ; H1/p4= huPAD4 recombinant Histon 1 and so forth (x-axis). EXAMPLES
Example 1 : Recombinant human and mouse monoclonal antibodies.
Monoclonal antibodies against citrullinated antigens of patients with RA were initially selected by means of phage display, as described (Raats et al., J
Reumatology, vol30, 1696-71 1 , 2003). Briefly, the autoantibody repertoires of three patients with RA were isolated from their B-cell repertoire, and used to generate antibody fragment libraries. These libraries were subjected to four rounds of affinity selection against citrullinated cyclic peptide CFC1 -cyc as described in WO98/22503. Antibody clones were selected based on their strong reactivity with CFC1 -cyc and lack of reactivity with the non-citrullinated CFCO-cyc, (WO98/22503).
Antibody coding sequences described by Raats et al., (J Reumatology, vol30, 1696-71 1 , 2003) were synthesized according to Stemmer et al (Gene, vol164, 49- 53, 1995), and subsequently cloned into mammalian expression vectors coding for human and mouse antibody isotypes. Human antibodies were of the isotype lgG1 lambda and were named RhmAb2.101 , RhmAb2.102.
RhmAb2.101 was synthesized according to the protocol of Stemmer et al., (Gene, vol164, 49-53, 1995) based on the sequence of clone Ra3 (Raats et al., J Reumatology, vol30, 1696-71 1 , 2003) and consists of a VH derived from germline family 3-21 , combined with a VL derived from germline family λ1 b..
RhmAb2.102 was synthesized according to Stemmer et al (Gene, vol164, 49-53, 1995) and comprises an immunoglobulin heavy chain encoded by SEQ ID NO: 8, combined with an immunoglobulin light chain encoded by SEQ ID NO: 9. The immunoglobulin heavy chain encoded by SEQ ID NO: 8 comprises a mouse leader globulin according to SEQ ID NO: 12, followed by the variable antibody heavy chain according to SEQ ID NO: 13, followed by the immunoglobulin constant domain human lgG1 according to SEQ ID NO: 14. The immunoglobulin light chain encoded by SEQ ID NO: 9, comprises a mouse leader globulin according to SEQ ID NO: 12, followed by the variable antibody light chain according to SEQ ID NO: 15 followed by the immunoglobulin human lambda constant domain according to SEQ ID NO: 16.
The primary mRNA sequences of the variable domains (VH and VL) of monoclonal antibody RhmAb2.101 have been published and were deposited in the EMBL database under accession numbers as shown in table 1. Full size human antibody sequences were generated using identical leader and constant human domains as described for antibody RhmAb2.102. Table 1
Figure imgf000034_0001
Control antibodies RmmAb13.101 , RmmAb13.102 and RmmAb13,103 against citrullinated fibrinogen, and RhmAb2.201 against the apoptotic 40 kD cleavage product of the Human U1 -70k protein, were commercially obtained from Modiquest
Research BV, Schoutstraat 58, 6525 XV Nijmegen, The Netherlands (Cat no, MQ13.101 , MQ13.102, MQ13.103,and MQR2.201 ).
Example 2: Experimental model for inflammation
The commercially available collagen antibody induced arthritis (CAIA) mouse model from ModiQuest Research B.V. (cat no: MQ18.101 ) has been used according to manufacturers specifications to induce arthritis in mice
(http://www.modiquestresearch.nl/shop/files/18.101 -50MG _2007.08.22.pdf). For that purpose, on day 0 male DBA/J1 mice (5-6 mice /group) of the age of 8 weeks have been injected i.p. with a mix of 8 anti-collagen antibodies. (Mice used in figure 1 a and 1 b received 1 ,6mg anti-collagen antibody mix, whereas mice used in figure 1 c-f received 2,4mg). On day 3, mice received another i.p. injection containing 25ug LPS mixed with 1 mg anti-citrulline antibodies (unless stated otherwise). LPS triggers the inflammation. Until day 13 of the experiment animals where scored daily for signs of inflammation in their paws. Scoring has been performed according to the table 2. The maximum arthritis score per animal is 8.
Mouse monoclonal anti-citrulline antibodies RmmAb13.101 ,
RmmAb13.102 and RmmAb 13.103 were confirmed to be able to enhance the severity of the collagen antibody induced arthritis. A mixture of these antibodies had even a more pronounced response. This essentially confirms earlier results that anti-citrullin antibodies are capable of enhancing/inducing arthritis (Kuhn et al., J. Clin. Invest, vol1 16, 961 -871 , 2006; Hill et al., J Exp Med, vol205, 967-979, 2008). These results are shown in Figure 1 a and b, which shows the "mean arthritis score" and "arthritis incidence" respectively of the same experiment.
Human monoclonal antibody RhmAb2.102, reduced or even abolished the clinical signs of arthritis in the experimental CAIA model, whereas RhmAb2.101 had no effect at all at the dose tested (Figure 1 c and 1 d).
Table 2
Figure imgf000035_0001
The decision to administrate anti-citrullin antibodies on day 3 after anti-collagen antibody injection was based on the data of the experiment described herein above which show that citrullinated epitopes appeared in the paws of mice with experimentally induced arthritis approximately at day 4.
Example 3: Preparation of deiminated cell extract, SDS-page electrophoresis and western blotting.
COS-1 cells (8 105) were transiently transfected with 2μg huPAD2 or huPAD4 expression vector using the AMAXA nucleofection device (program D-005) together with the V-kit, and cells were seeded in 20ml medium in a T75.
72 hours later the cells were washed twice with PBS, trypsinized, spun down and resuspended in 15μΙ ice cold lysis buffer (20mM Tris pH7.4, 10mM β- mercaptoethanol, 100mM NaCI, 10% glycerol, protease inhibitors).
The cell samples were sonified 4 times for 15 seconds on ice. The lysate was centrifuged at 3.000 rpm for 5 minutes and the supernatant transferred to a clean tube. The cell lysate was deiminated for 30 minutes to 2 hours at 37°C by adding CaCI2 and DTE at a final concentration of 10 and 5mM respectively. Deiminated cell lysates were stored at -20°C.
10x sample buffer (0.25M Tris pH6.8, 8% SDS, 35% glycerol, 2.5% β- mercaptoethanol, bromphenolblue) was added to the deiminated cell lysates and boiled for 5 minutes. Lysate corresponding to approximately 5 105 cells was loaded in each lane of a SDS-PAGE (15% gels) and separated, followed by electroblotting to Hybond C extra nitrocellulose membranes (Amersham Biosciences). Blotting and loading were checked by Ponceau S staining. Example 4: Therapeutic anti-citrulline antibodies recognize p15 and p17
Blots as prepared in example 3 were cut in strips and blocked for 2 hours at RT with 5% (w/v) low fat dry milk in PBS-Tween (wash buffer) to block all nonspecific sites. Blots were then washed 5 times 5 minutes with wash buffer and strips were incubated for an additional 1 hour at RT with 4 ml wash buffer containing 20ug anti- citrulline antibody. Thereafter, the strips were washed 5 times for 10 min with wash buffer, and incubated with a peroxydase-conjugated rabbit anti-human IgG (Dako) (1 hour at RT) in wash buffer (1 :2000). Strips where then washed 3 times for 10min with wash buffer followed by a 2 times wash with PBS to wash away all unbound antibody.
Immunoreactive bands were visualized using chemiluminescent substrate (PIERCE), and exposed to Kodak BioMax XAR autoradiography films (Eastman Kodak Company, Rochester, NY, USA).
It was observed, that strips incubated with RhmAb2.102 showed reactivity with a doublet of proteins with a molecular weight of approximately 15 and 17 kiloDalton.
Example 5 Immunoprecipitation of antigens:
For immunoprecipitation purposes, 20μg anti-citrulline antibodies together with 30μΙ_ of protein A-Sepharose fast flow (Amersham Biosciences, Uppsala, Sweden) was added to 330 μΙ_ cell lysate and incubated 2 hours at 4°C while rotating. The Sepharose beads with immunobound proteins were subsequently washed four times in IPP150 (10 mM Tris/Hcl pH8, 150mM NaCI, 0.1 % NP40, 0.1 % Tween-20). 2 χ sample buffer (100 mm Tris-HCI, pH 6.8, 200 mm dithiothreitol, 4% SDS, 0.2% bromophenol blue, 20% glycerol) was added to the beads, and proteins were subjected to 15% SDS-PAGE. The gel was stained overnight at RT in staining solution (10% w/v ammonium sulfate, 2% w/v phosphoric acid (85%), 0.1 % w/v CBB G-250, 20% v/v methanol) while gently rocking. All staining trays were sealed with parafilm to prevent methanol evaporation. The next day background de-staining was performed by incubating the gels in milli-Q H20 until desired staining is visible. The de-staining solution (milli-Q H20) was replaced 2-3 times, where after images of the gel where taken.
Immunoprecipitations with RhmAb2.102 on both human PAD2 and
PAD4 deiminated COS-1 lysates revealed prominent p15 and p17 protein bands which could not or hardly be detected in the RhmAb 2.101 precipitates.. The rate of recognition of p15 and p17 proteins therefore correlates well with the therapeutic properties of these antibodies (Figure 1 a-d). Example 6: Mass-spectrometry analysis of p15 and p17.
The bands at p15 and p17 of the SDS-page gels of example 3 were excised from the gel and analyzed by MALDI-TOF MS. Briefly, excised gel pieces were washed 2 times with 50 μΙ of 25 mM ammonium bicarbonate, and incubated 30 min for each washing step. A 15 min wash was repeated as above with the addition of 30% v/v acetonitrile. All liquid was removed and 25 μΙ of 25 mM ammonium bicarbonate + 25 μΙ of acetonitrile added and Incubated for 15 min. Again all liquid was removed and gels were incubated 30 min with 50 μΙ of acetonitrile. All liquid was removed and the pieces were dehydrated by incubating for 2 h at 37°C. After the dehydration, the gel pieces were allowed to swell again by adding 5 μΙ of trypsin solution (~ 15 ng trypsin/μΙ in 25 mM ammonium bicarbonate/5 mM n-octyl^-D-glucopyranoside) and incubated on ice for 1 hour. Excess trypsin solution was removed and gel pieces were incubate for 14 h at 37°C with 5 μΙ 25 mM ammonium bicarbonate/5 mM n-octyl^-D-glucopyranoside. Peptides were extracted by incubating with 4 μΙ 50% acetonitrile/0.5% trifluoroacetic acid (TFA)/5 mM n-octyl^-D-glucopyranoside for 1 h at RT. Samples were sonicated for 2 min in a sonication water bath, the liquid transferred in a new tube and the extraction step was repeated. The sample was dried in a vacuum centrifuge and subjected to MALDI-TOF MS.
All fragments identified in MALDI-TOF MS analysis were attributable to histone proteins (Table 3).
Table 3 MALDI-TOF data
Description Peptide Seq ID NO:
histone cluster 3, H2bb [Mus musculus] KAMGIMNSFVNDIFERI Seq ID NO: 1 histone cluster 3, H2bb [Mus musculus] RKESYSIYVYKV Seq ID NO: 2 similar to histone H2B [Bos taurus] KAMGIMNSFVNDIFKRI Seq ID NO: 3 histone cluster 1 , H2bn [Bos taurus] KAMGNMNSFVNDIFERI Seq ID NO: 4 histone cluster 2, H4 [Rattus norvegicus] RKTVTAMDVVYALKR Seq ID NO: 5 histone cluster 2, H4 [Rattus norvegicus] RDAVTYTEHAKR Seq ID NO: 6 histone cluster 2, H4 [Rattus norvegicus] RISGLIYEETRG Seq ID NO: 7 Example 7: Therapeutic anti-citrulline antibody RhmAb2.102 recognizes H2A p4.
Human recombinant histones H1 , H2A, H2B, H3 and H4 (10C^g) were incubated 3 hours with or without 53,4 mU huPAD2 or huPAD4 at 37°C. Deiminated as well as non-deiminated histones were coated on 96-well ELISA plates (O^g /well) by overnight incubation at 4°C. Wells were washed 5 times with PBS-Tween20 (PBS-T) and blocked by a 1 hour incubation with PBS-T + 1 % Bovine serum albumin (BSA) at room temperature (RT). After 5 more washes with PBS-T, wells were incubated for 1 hour at RT with serial dilutions of RhmAb2.101 or RhmAb2.102 in PBS-T + 1 % BSA starting at a concentration of 1 C^g/well. Wells were washed 5 times with PBS-T and incubated with rabbit-anti-human-HRP (1 :2000) for 1 hour at RT followed by 5 washes with PBS-T and 3 wash steps with PBS. Wells incubated with RhmAb2.101 were incubated 15min and wells incubated with RhmAb2.102 were incubated 10min with TMB substrate before stopping the reaction with 2M H2S04. Optical density was measured by 450nm and is a measure for the affinity of the antibodies used.
Example 8: Therapeutic anti-citrulline antibody RhmAb2.102 recognizes peptide 1.
96-well ELISA plates were coated with neutravidin (0,1 μg /well) by overnight incubation at 4°C. Wells were washed 5 times with PBS-Tween20 (PBS-T) and blocked by a 1 hour incubation with PBS-T + 1 % Bovine serum albumin (BSA) at room temperature (RT). After 5 more washes with PBS-T, wells were incubated for 1 hour at RT with histone derived citrulline and biotin containing peptides (0^g /well). After another 5 more washes with PBS-T, wells were incubated for 1 hour at RT with serial dilutions of RhmAb2.101 , RhmAb2.102 or RhmAb2.104 in PBS-T + 1 % BSA starting at a concentration of
10μg/well. Wells were washed 5 times with PBS-T and incubated with rabbit-anti-human- HRP (1 :2000) for 1 hour at RT followed by 5 washes with PBS-T and 3 wash steps with
PBS. Wells were incubated 5min with TMB substrate before stopping the reaction with 2M H2S04. Optical density was measured by 450nm and is a measure for the affinity of the antibodies used. Example 9: Therapeutic anti-citrulline antibodies recognize fibrinogen and vimentin derived citrulline peptides.
96-well ELISA plates were coated with neutravidin (0,1 μg /well) by overnight incubation at 4 degrees C. Wells were washed 5 times with PBS-Tween20 (PBS-T) and blocked by a 1 hour incubation with PBS-T + 1 % Bovine serum albumin (BSA) at room temperature (RT). After 5 more washes with PBS-T, wells were incubated for 1 hour at RT with fibrinogen and vimentin derived citrulline and biotin containing peptides (O^g /well). After another 5 more washes with PBS-T, wells were incubated for 1 hour at RT with serial dilutions of RhmAb2.101 or RhmAb2.102 in PBS-T + 1 % BSA starting at a concentration of 10 μg/well. Wells were washed 5 times with PBS-T and incubated with rabbit-anti-human- HRP (1 :2000) for 1 hour at RT followed by 5 washes with PBS-T and 3 wash steps with PBS. Wells were incubated 5min with TMB substrate before stopping the reaction with 2M H2S04. Optical density was measured by 450nm and is a measure for the affinity of the antibodies used. Example 10: Therapeutic potential of RhmAb2.102
The commercially available collagen antibody induced arthritis (CAIA) mouse model from ModiQuest Research B.V. (cat no: MQ18.101 ) has been used according to manufacturers specifications to induce arthritis in mice
(http://www.modiquestresearch.nl/shop/files/18.101 -50MG%20_2007.08.22.pdf). For that purpose, on day 0 male DBA/J1 mice (5 mice/group) of the age of 8 weeks have been injected i.p. with a mix of 8 anti-collagen antibodies (2,8mg/mouse). On day 3, mice received another i.p. injection containing 25ug LPS. LPS triggers the inflammation. On day 7 when the mean arthritis score was around 4 (Figure 6A) one group received an i.v. injection containing 1 mg RhmAb2.102, whether the other group received an i.v. injection containing placebo.
Animals where scored daily for signs of inflammation in their paws. Scoring has been performed according to table 2. The maximum arthritis score per animal is 8. RhmAb2.102 stabilized the inflammation (Figure 6A).
All right hind paws have been used for histological analysis. Tissue was fixed for 4 days in 4% formaldehyde, decalcified in 5% formic acid, and subsequently dehydrated and embedded in paraffin. Standard frontal sections of 7μηι were mounted on SuperFrost slides (Menzel-Glaser, Braunschweig, Germany). Haematoxylin and eosin (H&E) staining was performed to study joint inflammation (cell influx, Figure 7D). The severity of inflammation in the joints was scored on a scale of 0-3 (0 = no cells, 1 = mild cellularity, 2 = moderate cellularity, and 3 = maximal cellularity). Figure 7A shows the macroscopical inflammation on day 35. To study proteoglycan (PG) depletion from the cartilage matrix (Figure 7E), sections were stained with safranin O (SO) followed by counterstaining with fast green. Depletion of PG was determined using an arbitrary scale of 0-3, ranging from normal, fully stained cartilage to destained cartilage, fully depleted of PGs. Chondrocyte death (Figure 7F) was scored on a scale of 0 - 3 ranging from no loss of chondrocyte nuclei to complete empty cartilage surface. Cartilage and bone erosion (Figure 7B & C) were graded on a scale 0 - 3, ranging from no damage to complete loss of the cartilage or bone structure. Histopathological changes in the joint were scored on five semiserial sections of joint spaced 70μηι apart. Scoring was performed blind, without previous knowledge of the experimental conditions.
Although macroscopical inflammation in the right hind paws among groups was identical on day 35 (Figure 6A and 7A), a dramatic decrease is observed in the experimental group receiving RhmAb2.102 compared to the control group when looking at any of the following parameters for joint erosion: Inflammatory cell influx (Figure 7D), Cartilage erosion (Figure 7B), Cartilage PG depletion (Figure 7E), Chondrocyte death (Figure 7F) and Bone erosion (Figure 7C). This result strongly supports the therapeutic potential of RhmAb2.102.
Example 1 1 : Preparation of huPAD4 deiminated HEK293 extract and immunoprecipitation with RhmAb2.101 or RhmAb2.102
HEK293 cells were harvested, washed once with PBS, spun down, and
5.105 cells cells resuspended in 15μΙ ice cold lysis buffer (20mM Tris pH7.4, 10mM β- mercaptoethanol, 100mM NaCI, 10% glycerol, protease inhibitors).
The cell samples were sonified 4 times for 15 seconds on ice. The lysate was centrifuged at 3.000 rpm for 5 minutes and the supernatant transferred to a clean tube. The cell lysate was deiminated for 2 hours at 37°C by adding 1 U human PAD4 per
2mg of protein (ModiQuest Research B.V.; cat no: MQ16.203), 10mM CaCI2 and 5mM
DTT.
Deimination of lysates was verified by subjecting the deiminated HEK293 lysates to SDS-Page (12,5% gels) electrophoresis followed by Western blotting. Western blots have been immunostained with antibodies RhmAb2.101 or RhmAb2.102 and found positive. Blots treated with an irrelevant antibody did not show any staining.
Subsequently, immunoprecipitations (IP) have been performed on deiminated HEK293 lysates with antibodies RhmAb2.101 or RhmAb2.102. Briefly, 30μΙ Protein A Sepharose Fast Flow were washed 5 times with 1 ml IPP500 (10mM Tris/HCI pH8,0, 500mM NaCI, 0,1 % NP40 and 0,1 % Tween-20), and coupled to 20μg
RhmAb2.101 , 20μg RhmAb2.102 or not coupled (negative control). Protein A Sepharose Beads / antibody mixtures have been incubated 1 h at room temperature under constant rotation. Beads were subjected to 3 washes with 1 ml IPP500, one wash with 1 ml IPP150 (10mM Tris/HCI pH8,0, 150mM NaCI, 0,1 % NP40 and 0,1 % Tween-20), and subsequently incubated at room temperature with 300μΙ deiminated HEK293 lysate for 2 hours under constant rotation. Beads were washed 3 times with 1 ml of IPP150 after which a small part has been used for SDS-PAGE electeforesis to determine if the IP procedure with the HEK293 cells was successful. Immunoprecipitated proteins on RhmAb2.101 ,
RhmAb2.102 and control beads have been eluted with 50μΙ elution buffer (100mM Na citrate pH3.0) , neutralized with 10μΙ 1 M Tris/HCI pH9,04 and stored at -20°C until nl_C LTQ FTMS ULTRA mass spectrometry (Example 12).
Example 12: Mass-spectrometry analysis of RhmAb2.101 and RhmAb2.102
immunoprecipitated huPAD4 deiminated HEK293 proteins
To remove PEG's from the immunoprecipitated proteins, they were loaded on a 15% SDS-PAGE gel and run shortly. The proteins were cut out of the gel and in-gel digested with trypsin as described in example 6. Samples where diluted 50 fold before subjecting them to nl_C LTQ FTMS ULTRA analysis.
Peptide and protein identifications were extracted from the data by means of the search program Mascot, using the NCBInr_20081022 database with Homo sapiens taxonomy. The following modifications were allowed in the search: carbamidomethylation of cysteines (C) (fixed), oxidation of methionine (M) (variable) and deamidation of asparagine (N), arginine (R) and glutamine (Q) (variable). Deimination could not be used as a search tool. This problem could be eliminated since deamidation and deimination result both in 1 dalton mass difference if compared to non modified arginines.
Protein identification validation was performed by an in-house developed script. Briefly, the software classifies protein identifications based on the number of uniquely identified peptide sequences, clusters proteins sharing the same set of peptides and validates the proteins with the following criteria:
Proteins with 1 peptide must have a peptide score: >49
Proteins with more than 1 peptide must have a peptide score: >29
With the validation criteria used, peptides have been identified in all 3 samples (sample 1 : HEK293 precipitate with RhmAb2.101 ; sample 2: HEK293 precipitate with Rhm2.102; sample 3: HEK293 precipitate with empty beads).
emPAI (Exponentially Modified Protein Abundance Index) was calculated for all validated proteins. emPAI provides approximate, label-free, relative quantitation of the proteins in a mixture based on protein coverage by the peptide matches in a database search result. This technique enabled us to identify deiminated proteins that
(preferentially) bind to RhmAb2.102. This is shown in Table 9. Table 9 nLC LTQ FTMS ULTRA data
Protein ID Protein Ratio 102/ 101 gi 45038411 ref 1 N P_001460.11 ATP-dependent DNA helicase II, 70 kDa subunit [Homo sapiens]
gi 45042791 ref 1 N P_002098.11 H3 histone, family 3A [Homo sapiens]
gi 45042631 ref | NP_003512.11 H2B histone family, member E [Homo sapiens]
gi 163065661 ref | NP_003518.2 | histone H2B [Homo sapiens]
gi 108001301 ref 1 N P_066409.11 histone 1, H2ad [Homo sapiens]
gi 45019551 ref 1 N P_001609.11 poly (ADP-ribose) polymerase family, member 1 [Homo sapiens]
gi 600979021 ref 1 N P_002007.11 filaggrin [Homo sapiens]
gi 133992981 ref | N P_064455.11 immunoglobulin lambda-like polypeptide 1 isoform a precursor [Homo sapiens]
gi 1134148931 ref | XP_001127175.11 PREDICTED: similar to lactotransferrin [Homo sapiens]
gi 621229171 ref | NP_001014364.11 filaggrin 2 [Homo sapiens]
gi 45575811 ref | NP_001435.11 fatty acid binding protein 5 (psoriasis-associated) [Homo sapiens]
gi 137752121 ref | NP_112583.11 polyamine modulated factor 1 binding protein 1 [Homo sapiens]
gi 216145441 ref | NP_002955.2 | S100 calcium-binding protein A8 [Homo sapiens]
gi 47581701 ref 1 N P_004397.11 deleted in malignant brain tumors 1 isoform a precursor [Homo sapiens]
gi 45031431 ref 1 N P_001900.11 cathepsin D preproprotein [Homo sapiens] ~ gi 775397581 ref | N P_001029249.11 histone cluster 2, H4b [Homo sapiens] 30,2 gi 45018831 ref 1 N P_001604.11 alpha 2 actin [Homo sapiens] 3,2 gi 120564681 ref | NP_068831.11 junction plakoglobin [Homo sapiens] 2,8 gi 45018851 ref 1 N P_001092.11 beta actin [Homo sapiens] 2,7 gi 585308401 ref | N P_004406.21 desmoplakin isoform 1 [Homo sapiens] 2,2
gi 1578645821 ref | NP_001009931.11 hornerin [Homo sapiens] 1,7 gi 1741368831 ref | NP_114032.21 heterogeneous nuclear ribonucleoprotein U isoform a [Homo sapiens] 1,0 gi 1344196351 ref | N P_002146.21 heat shock 70kDa protein 6 (HSP70B') [Homo sapiens] 1,0 gi 1508453881 ref | N P_001002858.11 annexin A2 isoform 1 [Homo sapiens] 1,0
PREDICTED: similar to 60S ribosomal protein L29 (Cell surface heparin-binding
gi 11134252631 ref | XP_001133831.11 protein HIP) [Homo sapiens] 1,0 gi 148854311 ref | NP_005337.11 heat shock 70kDa protein IB [Homo sapiens] 0,8 gi 11171902541 ref 1 NP_001070911.11 heterogeneous nuclear ribonucleoprotein C isoform b [Homo sapiens] 0,7 gi 1324834161 ref | N P_066554.21 neurofilament, heavy polypeptide 200kDa [Homo sapiens] 0,7 gi 145066291 ref | N P_000983.11 ribosomal protein L29 [Homo sapiens] 0,5 gi 157298771 ref | N P_006588.11 heat shock 70kDa protein 8 isoform 1 [Homo sapiens] 0,5 gi 145034711 ref | NP_001393.11 eukaryotic translation elongation factor 1 alpha 1 [Homo sapiens] 0,5 gi 1167519211 ref | NP_444513.11 dermcidin preproprotein [Homo sapiens] 0,4 gi 145020271 ref 1 N P_000468.11 albumin precursor [Homo sapiens] 0,4 gi 1340989461 ref | N P_004550.21 nuclease sensitive element binding protein 1 [Homo sapiens] 0,0
Example 13. Generation/selection of a family of anti-inflammatory antibodies
Human-derived scFv libraries were panned against PAD2-, or PAD4- deiminated forms of human Histon-2A, Histon-4, peptide 1 (AAASGXGKQGGK, SEQ ID NO: 21 ) and against CFC-1 peptide in a similar method as decribed in Raats et al., 2003 (Raats, J.M.H., Wijnen, E.W, Pruijn, G.J.M., Van den Hoogen, F.H.M., and W.J. van Venrooij. 2003. J. Rheum. 30, 1696-171 1 ).
Selected antibodies that showed citrulline dependent reactivity with CFC-1 and/ or peptide 1 (AAASGXGKQGGK, SEQ ID 21 ) and/or PAD-deiminated Histon 2a and/or Histon 4, were screened for reactivity against an array of citrullinated proteins and/or peptides derived thereof (Example 12, table 9), against PAD2 and PAD4 deiminated human Histon isoforms, and against deiminated human Histon-derived peptides. Concomitantly, immunoprecipitation was performed on PAD2 and PAD4 deiminated human cell extracts and sinovial fluid from RA patients.
Antibodies that immunoprecipitated bands p15 and/or p17, and/or antibodies with ELISA reactivity profiles against citrullinated epitopes (PAD2 and PAD4 deiminated human Histon isoforms, and/or CFC-1 and/ or peptide 1 (AAASGXGKQGGK, SEQ ID 21 , and/or citrullinated epitopes derived from proteins listed in 9comparable with
RhmAb2.102, were subsequently cloned into human lgG1 format. Full size human IgG antibodies were tested for their prophylactic and/or therapeutic anti-inflammatory potential in a CAIA mouse model, as described herein.
This screening procedure yielded antibodies with prophylactic and or therapeutic anti inflammatory potential in the CAIA mouse model with high frequency.
Examples of novel antibodies selected according to the above method are RhmAb2.108, RhmAb2.109, RhmAb2.1 10, RhmAb2.1 1 1 and RhmAb2.1 12, are disclosed herein in SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 39, SEQ ID NO: 20, SEQ ID NO: 41 , SEQ ID NO: 40, SEQ ID NO: 19, SEQ ID NO: 43, SEQ ID NO: 42. The RhmAb2.1 10 immunoglobulin light chain encoded by SEQ ID NO: 10, comprises a mouse leader globulin according to SEQ ID NO: 12, followed by the variable antibody light chain according to SEQ ID NO: 41 followed by the immunoglobulin human kappa constant domain according to SEQ ID NO: 1 1.
Subsequently the Collagen antibody induced arthritis (CAIA) model was used to test the anti inflammatory effect of RhmAb2.108, RhmAb2.109, RhmAb2.1 10, RhmAb2.1 1 1 and RhmAb2.1 12, compared to RhmAb2.102. For this purpose all antibodies were produced transiently in HEK293 cells. Groups of 3 DBA/J1 mice were treated at day 0 with i.p. injection of 2,8mg anti-collagen antibodies (MQ18.101 ). LPS (25 g/mouse) as well as RhmAb2.108, RhmAb2.109, RhmAb2.H 0, RhmAb2.1 1 1 ,
RhmAb2.1 12, and RhmAb2.102 (1 mg/mouse) and placebo were administered via i.p. injection on day 3. All animals have been scored for inflammation daily until day 10.
In this experiment all novel generated antibodies showed a better anti inflammatory response compared to RhmAb2.102, RhmAb 2.1 109, RhmAb, 2.1 10, completely abolished inflammation, whereas MhmAb 2.1 12, nearly abolished, and RhmAb 2.1 1 1 , and rhmAb 2.108 strongly reduced the signs of inflammation in the tested animals. Figure 9. Example 14: Mouse monoclonal antibodies.
Antibodies against a synthetic citrulline containing peptide according to the invention have been raised in DBA J1 mice. At day 125 after start of the immunization process serum samples were taken and analyzed for a citrullin specific antigen response. All mice showed a specific antigen specific serum titre at the time points tested.
In order to produce hybridoma cell-lines, spleens have been dissected after the last boost, splenocytes were harvested from the spleen and fused with a mouse myeloma cell-line (NS-1 ) according to ModiQuest B.V. procedures. Antibody specificity in hybridoma supernatants have been screened on cirtulline containing antigen as well as on the non-ctirullinated equivalent.
This resulted in the hybridoma clones (DSMZ Accession no ACC 3031 and ACC 3032), producing RmmAb22.101 and RmmAb22.102 respectively; SEQ ID NO 44 and SEQ ID NO 45.
Subsequently the Collagen antibody induced arthritis (CAIA) model was used to test the anti inflammatory effect of RmmAb22.101 and RmmAb22.102 compared to RhmAb2.102. Groups of 3 DBA J1 mice were treated at day 0 with i.p. injection of 2,8mg anti-collagen antibodies (MQ18.101 ). LPS (25 μg mouse) as well as
RmmAb22.101 , RmmAb22.102 and RhmAb2.102 (6mg/mouse) and placebo were administered via i.p. injection on day 3. All animals have been scored for inflammation daily until day 10.
RhmAb2.102, RmmAb22.101 and RmmAb22.102 antibodies completely protected the mice against inflammation in their paws. Figure 10.
Example 15: Novel therapeutic anti-citrulline antibodies display similar recognition patterns to citrullinated epitopes compared to RhmAb 2.102.
Similar to the experiments described in example 7 and 8 the newly generated antibodies RhmAb2.108, RhmAb2.109, RhmAb2.1 10, RhmAb2.1 1 1 , RhmAb2.1 12, RmmAb22.101 , and RmmAb22.102 were analysed in ELISA for their reactivity on various deiminated targets compared to RhmAb 2.102.
Human recombinant histones H1 , H2A, H2B, H3 and H4 (100μg) were deiminated as described in Example 7.
Deiminated as well as non-deiminated histones were coated on 96-well
ELISA plates (O^g /well) by overnight incubation at 4°C.
Next to the deiminated histones antibodies were also tested in a set of biotinylated peptides. Both in their citrullinated as well as non-citrullinated forms. Coating of peptides was performed as described in example 8.
All Coated wells were washed 5 times with PBS-Tween20 (PBS-T) and blocked by a 1 hour incubation with PBS-T + 1 % Bovine serum albumin (BSA) at room temperature (RT). After 5 more washes with PBS-T, wells were incubated for 1 hour at RT with serial dilutions of the antibodies in PBS-T + 1 % BSA starting at a concentration of 2^g/well. Wells were washed 5 times with PBS-T and incubated with rabbit-anti-human- HRP (1 :2000) for 1 hour at RT followed by 5 washes with PBS-T and 3 wash steps with PBS. Stain 10 min with TMB substrate before stopping the reaction with 2M H2S04.
Optical density was measured by 450nm and is a relative measure for the affinity of the antibodies used. This showed clearly that all therapeutic antibodies have a highly similar staining pattern compared to the therapeutic antibody RhmAb2.102. Only the mouse monoclonals show no reactivity with the Cfc1 - peptide. All therapeutic antibodies, have very high reactivity with the a peptide according to SEQ ID No: 21 , as well as with Histon 2A/p2 Histon 2A/p4, and histon 4/p2, and show slight reactivity with Histon 3/p2.
1 /1
PC .
Print Out (Original in Electronic Form)
(This sheet is not part of and does not count as a sheet of the international application)
Figure imgf000047_0001
Indications are Made All designations
FOR RECEIVING OFFICE USE ONLY
0-4 This form was received with the
international application:
(yes or no) yes
0-4-1 Authorized officer
Bruno Gatinet
FOR INTERNATIONAL BUREAU USE ONLY
0-5 This form was received by the
international Bureau on: 23 December 2010 (23.12.2010)
0-5-1 Authorized officer
Carole BAERT

Claims

46 CLAIMS
1 . Antibody specifically reactive with a citrullinated epitope on human PAD4 and/or PAD2 deiminated human histone 2A and/or histone 4, and/or on human PAD2 deiminated human histone H3 for use in the prevention or treatment of Rheumatoid Arthritis wherein the antibody comprises a specific binding domain obtainable from a nucleic acid sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 , SEQ ID NO: 19, SEQ ID NO: 43, SEQ ID NO: 42, SEQ ID NO: 44 and SEQ ID NO: 45.
2. Antibody for use according to claim 1 specifically reactive with a peptide selected from the group consisting of SEQ ID NO: 21 , SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 37 and SEQ ID NO: 38.
3. Antibody for use according to claims 1 or 2 selected from the group consisting of recombinant antibodies, single chain antibodies, Single Chain Variable Fragments (scFvs), fragment antigen binding regions (Fabs), single domain antibodies (sdabs), VHH antibodies, nanobodies, camelids derived single domain antibodies, shark IgNAR derived single domain antibody fragments (VNAR), Anticalins and aptamers.
4. Antibody for use according to claims 1 - 3 wherein the antibody is a monoclonal antibody selected from the group consisting of RhmAb2.108, RhmAb2.109, RhmAb2.1 10, RhmAb2.1 1 1 and RhmAb2.1 12, RmmAb22.101 , and RmmAb22.102.
5. Method for preventing or treating Rheumatoid arthritis, comprising the step of
administering to a patient in need thereof a therapeutically effective amount of an anti-inflammatory composition comprising an antibody comprising at least one antigen binding region selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 , SEQ ID NO: 19, SEQ ID NO: 43, SEQ ID NO: 42, SEQ ID NO: 44 and SEQ ID NO: 45.
6. Method according to claim 5, wherein the antibody comprises at least a heavy chain domain selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 40, SEQ ID NO: 42 and SEQ ID NO: 44, in combination with a light chain domain selected from the group consisting of SEQ ID NO: 17, SEQ ID NO: 39, SEQ ID NO: 41 , SEQ ID NO: 19, SEQ ID NO: 43 and SEQ ID NO: 45.
7. Polypeptide comprising an amino acid sequence encoded by a variable heavy or 47 light chain domain selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 17, SEQ ID NO: 39, SEQ ID NO: 41 , SEQ ID NO: 19, SEQ ID NO: 43 and SEQ ID NO: 45.
8. Nucleic acid encoding a polypeptide according to claim 7.
9. Nucleic acid according to claim 8 comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 17, SEQ ID NO: 39, SEQ ID NO: 41 , SEQ ID NO: 19, SEQ ID NO: 43 and SEQ ID NO: 45.
PCT/EP2010/069431 2009-12-10 2010-12-10 Anti-inflammatory agents directed against citrullinated epitopes WO2011070172A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP10788080.9A EP2509999B1 (en) 2009-12-10 2010-12-10 Anti-inflammatory agents directed against citrullinated epitopes
KR1020127017692A KR101786136B1 (en) 2009-12-10 2010-12-10 Anti-inflammatory agents directed against citrullinated epitopes
US15/449,623 USRE46990E1 (en) 2009-12-10 2010-12-10 Anti-inflammatory agents
ES10788080.9T ES2587083T3 (en) 2009-12-10 2010-12-10 Anti-inflammatory agents directed against citrullinated epitopes
CA2783691A CA2783691C (en) 2009-12-10 2010-12-10 Anti-inflammatory agents directed against citrullinated epitopes
JP2012542572A JP5980683B2 (en) 2009-12-10 2010-12-10 Anti-inflammatory agents against citrullinated epitopes
AU2010329842A AU2010329842B2 (en) 2009-12-10 2010-12-10 Anti-inflammatory agents directed against citrullinated epitopes
US13/514,923 US9109019B2 (en) 2009-12-10 2010-12-10 Anti-inflammatory agents
US14/742,990 US10233236B2 (en) 2009-12-10 2015-06-18 Method of treating or preventing rheumatoid arthritis
US16/227,047 US20190119368A1 (en) 2009-12-10 2018-12-20 Method of Treating or Preventing Rheumatoid Arthritis
US16/984,515 US20210087260A1 (en) 2009-12-10 2020-08-04 Method of Treating or Preventing Rheumatoid Arthritis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09178658A EP2332987A1 (en) 2009-12-10 2009-12-10 Anti-inflammatory agents directed against citrullinated epitopes
EP09178658.2 2009-12-10

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/514,923 A-371-Of-International US9109019B2 (en) 2009-12-10 2010-12-10 Anti-inflammatory agents
US14/742,990 Division US10233236B2 (en) 2009-12-10 2015-06-18 Method of treating or preventing rheumatoid arthritis

Publications (1)

Publication Number Publication Date
WO2011070172A1 true WO2011070172A1 (en) 2011-06-16

Family

ID=42061173

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/069431 WO2011070172A1 (en) 2009-12-10 2010-12-10 Anti-inflammatory agents directed against citrullinated epitopes

Country Status (8)

Country Link
US (5) US9109019B2 (en)
EP (3) EP2332987A1 (en)
JP (1) JP5980683B2 (en)
KR (1) KR101786136B1 (en)
AU (1) AU2010329842B2 (en)
CA (2) CA2783691C (en)
ES (1) ES2587083T3 (en)
WO (1) WO2011070172A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013109185A1 (en) * 2012-01-19 2013-07-25 Vilara Ab Novel antibodies
WO2015116896A1 (en) * 2014-01-31 2015-08-06 The General Hospital Corporation Treatment of sepsis and septic shock
US9109019B2 (en) 2009-12-10 2015-08-18 Modiquest B.V. Anti-inflammatory agents
WO2016092082A1 (en) * 2014-12-11 2016-06-16 Modiquest B.V. Method for the treatment of idiopathic pulmonary fibrosis
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
WO2020038963A1 (en) 2018-08-21 2020-02-27 Modiquest B.V. Antibodies binding to citrullinated histone 2a and/or 4
EP4085973A1 (en) 2021-05-04 2022-11-09 Citryll B.V. Inhibition of eosinophil extracellular traps
WO2022233931A1 (en) 2021-05-04 2022-11-10 Citryll B.V. Inhibition of eosinophilic traps
US11866512B2 (en) * 2017-11-22 2024-01-09 Vacara Ab Antibodies to citrullinated proteins

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3007411B1 (en) * 2013-06-21 2015-07-03 Agronomique Inst Nat Rech MONOCATENARY ANTIBODY TO CAMPHIDE HEAVY CHAIN AGAINST CHROMATIN AND USES THEREOF
GB202103164D0 (en) * 2021-03-08 2021-04-21 Adiga Life Sciences Inc Therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022503A2 (en) 1996-11-15 1998-05-28 Stichting Scheikundig Onderzoek Nederland Peptide derived from an antigen recognized by autoantibodies from patients with rheumatoid arthritis, antibody directed against said peptide, a combinatorial antigen, and a method of detecting auto-immune antibodies
WO2004078098A2 (en) 2003-03-07 2004-09-16 London Health Sciences Centre Research Inc. Peptides associated with hla-dr mhc class ii molecules involved in autoimmune diseases
WO2009147201A2 (en) * 2008-06-04 2009-12-10 Modiquest B.V. Anti-inflammatory agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4777785B2 (en) 2006-01-31 2011-09-21 独立行政法人科学技術振興機構 Antibody enzyme against N-terminal region of chemokine receptor CCR5
EP2332987A1 (en) 2009-12-10 2011-06-15 ModiQuest B.V. Anti-inflammatory agents directed against citrullinated epitopes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022503A2 (en) 1996-11-15 1998-05-28 Stichting Scheikundig Onderzoek Nederland Peptide derived from an antigen recognized by autoantibodies from patients with rheumatoid arthritis, antibody directed against said peptide, a combinatorial antigen, and a method of detecting auto-immune antibodies
WO2004078098A2 (en) 2003-03-07 2004-09-16 London Health Sciences Centre Research Inc. Peptides associated with hla-dr mhc class ii molecules involved in autoimmune diseases
WO2009147201A2 (en) * 2008-06-04 2009-12-10 Modiquest B.V. Anti-inflammatory agents

Non-Patent Citations (34)

* Cited by examiner, † Cited by third party
Title
ARTHRITIS AND RHEUMATISM, vol. 39, no. 5, 1996, pages 713 - 722
BENIAC ET AL., J STRUCT BIOL, vol. 129, 2000, pages 80 - 95
BOGGS ET AL., J NEUROSCI RES, vol. 57, 1999, pages 529 - 535
CAO ET AL., BIOCHEMISTRY, vol. 38, 1999, pages 6157 - 6163
CHAVANAS ET AL., GENE, vol. 330, 2004, pages 19 - 27
ERNST WAGNER ET AL: "Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis", RHEUMATOLOGY INTERNATIONAL ; CLINICAL AND EXPERIMENTAL INVESTIGATIONS, SPRINGER, BERLIN, DE LNKD- DOI:10.1007/S00296-009-0854-2, vol. 29, no. 11, 28 January 2009 (2009-01-28), pages 1315 - 1321, XP019738721, ISSN: 1437-160X *
HILL ET AL., J EXP MED, vol. 205, 2008, pages 967 - 979
ISHIDA-YAMAMOTO ET AL., J INVEST DERMATOL, vol. 114, 2000, pages 701 - 705
KUHN ET AL., J. CLIN. INVEST, vol. 116, 2006, pages 961 - 871
KUNA ANDREA TESIJA ET AL: "Antibodies to mutated citrullinated vimentin and antibodies to cyclic citrullinated peptides in juvenile idiopathic arthritis.", CLINICAL CHEMISTRY AND LABORATORY MEDICINE : CCLM / FESCC 2009 LNKD- PUBMED:19842993, vol. 47, no. 12, 21 October 2009 (2009-10-21), pages 1525 - 1530, XP008127121, ISSN: 1434-6621 *
MASSON-BESSIÈRE ET AL., CLIN EXP IMMUNOL, vol. 119, 2000, pages 544 - 552
MASSON-BESSIÈRE ET AL., J. IMMUNOL, vol. 166, 2001, pages 4177 - 4184
MOSCARELLO ET AL., J NEUROCHEM, vol. 81, 2002, pages 335 - 343
MOSCARELLO ET AL., MULT SCLER, vol. 8, 2002, pages 130138
NANDAKUMAR; HOLMDAHL, J IMMUNOL METHODS, vol. 304, 2005, pages 126 - 136
NARAYANAN K ET AL: "Long-term follow up of infliximab therapy in inflammatory arthritis", INDIAN JOURNAL OF RHEUMATOLOGY,, vol. 2, no. 1, 1 March 2007 (2007-03-01), pages 8 - 10, XP026951497, ISSN: 0973-3698, [retrieved on 20070301] *
NEELI INDIRA ET AL: "Histone deimination as a response to inflammatory stimuli in neutrophils.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 FEB 2008 LNKD- PUBMED:18209087, vol. 180, no. 3, 1 February 2008 (2008-02-01), pages 1895 - 1902, XP002587421, ISSN: 0022-1767 *
NIJENHUIS ET AL., CLIN. CHIM. ACTA, vol. 350, 2004, pages 17 - 34
O'CONNOR ET AL., ANN NEUROL, vol. 46, 1999, pages 470
PRITZKER ET AL., BIOCHEMISTRY, vol. 39, 2000, pages 5374 - 5381
PRITZKER ET AL., BIOCHIM BIOPHYS ACTA, vol. 1388, 1998, pages 154 - 160
R. S. COTRAN; V. KUMAR; S. L. ROBBINS: "Robbins Pathological Basis of Disease", 1989, W. B. SAUNDERS CO., pages: 75
RAATS ET AL., J REUMATOLOGY, vol. 30, 2003, pages 1696 - 711
RAATS JOS M H ET AL: "Recombinant human monoclonal autoantibodies specific for citrulline-containing peptides from phage display libraries derived from patients with rheumatoid arthritis", 1 August 2003, JOURNAL OF RHEUMATOLOGY, JOURNAL OF RHEUMATOLOGY PUBLISHING COMPANY, TORONTO, CA, PAGE(S) 1696 - 1711, ISSN: 0315-162X, XP008098343 *
RAATS, J.M.H.; WIJNEN, E.W; PRUIJN, G.J.M.; VAN DEN HOOGEN, F.H.M.; W.J. VAN VENROOIJ., J. RHEUM., vol. 30, 2003, pages 1696 - 1711
REPARON-SCHUIJT ET AL., ARTHRITIS RHEUM, vol. 44, 2001, pages 41 - 47
SEBBAG MIREILLE ET AL: "Epitopes of human fibrin recognized by the rheumatoid arthritis-specific autoantibodies to citrullinated proteins.", EUROPEAN JOURNAL OF IMMUNOLOGY AUG 2006 LNKD- PUBMED:16838278, vol. 36, no. 8, August 2006 (2006-08-01), pages 2250 - 2263, XP002601412, ISSN: 0014-2980 *
SENSHU ET AL., ANAL BIOCHEM, vol. 203, 1992, pages 94 - 100
STEMMER ET AL., GENE, vol. 164, 1995, pages 49 - 53
VERPOORT K N ET AL: "Fine specificity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles.", ARTHRITIS AND RHEUMATISM DEC 2007 LNKD- PUBMED:18050209, vol. 56, no. 12, December 2007 (2007-12-01), pages 3949 - 3952, XP002601413, ISSN: 0004-3591 *
VOSSENAAR ET AL., BIOESSAYS, vol. 25, 2003, pages 1106 - 1118
VOSSENAAR; VAN VENROOIJ, ARTHRITIS RES THER, vol. 6, 2004, pages 107 - 111
WOOD ET AL., ANN NEUROL, vol. 40, 1996, pages 18 - 24
WOOD ET AL., J BIOL CHEM, vol. 264, 1989, pages 5121 - 5127

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9109019B2 (en) 2009-12-10 2015-08-18 Modiquest B.V. Anti-inflammatory agents
USRE46990E1 (en) 2009-12-10 2018-08-14 Modiquest B.V. Anti-inflammatory agents
US10233236B2 (en) 2009-12-10 2019-03-19 Modiquest B.V. Method of treating or preventing rheumatoid arthritis
WO2013109185A1 (en) * 2012-01-19 2013-07-25 Vilara Ab Novel antibodies
WO2015116896A1 (en) * 2014-01-31 2015-08-06 The General Hospital Corporation Treatment of sepsis and septic shock
US10131707B2 (en) 2014-01-31 2018-11-20 The General Hospital Corporation Treatment of sepsis and septic shock
AU2015359262B2 (en) * 2014-12-11 2021-02-04 Citryll B.V. Method for the treatment of idiopathic pulmonary fibrosis
WO2016092082A1 (en) * 2014-12-11 2016-06-16 Modiquest B.V. Method for the treatment of idiopathic pulmonary fibrosis
CN107108725A (en) * 2014-12-11 2017-08-29 莫蒂克斯特私人有限公司 The treatment method of idiopathic pulmonary fibrosis
US11066462B2 (en) 2014-12-11 2021-07-20 Citryll B.V. Method for the treatment of idiopathic pulmonary fibrosis
CN107108725B (en) * 2014-12-11 2021-03-23 莫蒂克斯特私人有限公司 Methods of treating idiopathic pulmonary fibrosis
US10849965B2 (en) 2015-05-05 2020-12-01 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
US11185577B2 (en) 2015-05-05 2021-11-30 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
US11925679B2 (en) 2015-05-05 2024-03-12 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
US11866512B2 (en) * 2017-11-22 2024-01-09 Vacara Ab Antibodies to citrullinated proteins
WO2020038963A1 (en) 2018-08-21 2020-02-27 Modiquest B.V. Antibodies binding to citrullinated histone 2a and/or 4
US11345750B2 (en) 2018-08-21 2022-05-31 Citryll B.V. Antibodies binding to citrullinated histone 2A and/or 4
EP4085973A1 (en) 2021-05-04 2022-11-09 Citryll B.V. Inhibition of eosinophil extracellular traps
WO2022233931A1 (en) 2021-05-04 2022-11-10 Citryll B.V. Inhibition of eosinophilic traps

Also Published As

Publication number Publication date
KR20120120492A (en) 2012-11-01
CA2783691C (en) 2019-05-07
JP5980683B2 (en) 2016-08-31
CA3027786A1 (en) 2011-06-16
ES2587083T3 (en) 2016-10-20
AU2010329842A1 (en) 2012-06-28
CA2783691A1 (en) 2011-06-16
US9109019B2 (en) 2015-08-18
US10233236B2 (en) 2019-03-19
USRE46990E1 (en) 2018-08-14
US20120321631A1 (en) 2012-12-20
EP2332987A1 (en) 2011-06-15
EP3095794A1 (en) 2016-11-23
US20190119368A1 (en) 2019-04-25
EP2509999B1 (en) 2016-05-11
US20150307603A1 (en) 2015-10-29
KR101786136B1 (en) 2017-10-17
EP2509999A1 (en) 2012-10-17
AU2010329842B2 (en) 2014-03-06
JP2013513374A (en) 2013-04-22
US20210087260A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
US10703822B2 (en) Anti-inflammatory agents
US20210087260A1 (en) Method of Treating or Preventing Rheumatoid Arthritis
US11345750B2 (en) Antibodies binding to citrullinated histone 2A and/or 4
AU2015359262A1 (en) Method for the treatment of idiopathic pulmonary fibrosis
Chirivi et al. Anti-citrullinated protein antibodies as novel therapeutic drugs in rheumatoid arthritis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10788080

Country of ref document: EP

Kind code of ref document: A1

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10788080

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010788080

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010329842

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2783691

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012542572

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2010329842

Country of ref document: AU

Date of ref document: 20101210

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20127017692

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13514923

Country of ref document: US